JP2012532931A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012532931A5 JP2012532931A5 JP2012520706A JP2012520706A JP2012532931A5 JP 2012532931 A5 JP2012532931 A5 JP 2012532931A5 JP 2012520706 A JP2012520706 A JP 2012520706A JP 2012520706 A JP2012520706 A JP 2012520706A JP 2012532931 A5 JP2012532931 A5 JP 2012532931A5
- Authority
- JP
- Japan
- Prior art keywords
- cyclopropyl
- triazol
- phenyl
- carboxamide
- bipyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 pyridin-1-yl Chemical group 0.000 claims 40
- 125000000753 cycloalkyl group Chemical group 0.000 claims 38
- 150000001875 compounds Chemical class 0.000 claims 35
- 125000000217 alkyl group Chemical group 0.000 claims 34
- 125000001475 halogen functional group Chemical group 0.000 claims 30
- 125000000623 heterocyclic group Chemical group 0.000 claims 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 18
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- 125000004432 carbon atom Chemical group C* 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 150000001408 amides Chemical class 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 7
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 150000003857 carboxamides Chemical class 0.000 claims 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- HSSJHMGCYYTGPL-UHFFFAOYSA-N 5-(6-cyclopropylpyridin-3-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-2,4-difluorobenzamide Chemical compound FC1=CC(F)=C(C=2C=NC(=CC=2)C2CC2)C=C1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 HSSJHMGCYYTGPL-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- HFWQWJJXZZFIMY-HNNXBMFYSA-N 3-(4,5-dimethylimidazol-1-yl)-n-[6-[4-[(2s)-1,1,1-trifluoropropan-2-yl]-1,2,4-triazol-3-yl]pyridin-2-yl]benzamide Chemical compound FC(F)(F)[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2C=C(C=CC=2)N2C(=C(C)N=C2)C)=N1 HFWQWJJXZZFIMY-HNNXBMFYSA-N 0.000 claims 2
- WUSUSCGYDUUQMW-UHFFFAOYSA-N 3-(4-cyclopropylimidazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]benzamide Chemical compound C=1C=CC(N2C=C(N=C2)C2CC2)=CC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 WUSUSCGYDUUQMW-UHFFFAOYSA-N 0.000 claims 2
- PDZGDWMWTABMGZ-IBGZPJMESA-N 3-(4-cyclopropylimidazol-1-yl)-n-[6-[4-[(1s)-1-phenylethyl]-1,2,4-triazol-3-yl]pyridin-2-yl]benzamide Chemical compound C1([C@H](C)N2C(=NN=C2)C=2N=C(NC(=O)C=3C=C(C=CC=3)N3C=C(N=C3)C3CC3)C=CC=2)=CC=CC=C1 PDZGDWMWTABMGZ-IBGZPJMESA-N 0.000 claims 2
- CPRSZYIJYCFPHV-UHFFFAOYSA-N 4-(2-cyclopropylpyrimidin-5-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=NC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 CPRSZYIJYCFPHV-UHFFFAOYSA-N 0.000 claims 2
- ZGCMQKWOUIMBEP-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(N2C=C(N=C2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 ZGCMQKWOUIMBEP-UHFFFAOYSA-N 0.000 claims 2
- CWZONKSGCPUCFJ-AWEZNQCLSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[3-[4-[(2s)-1,1,1-trifluoropropan-2-yl]-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound FC(F)(F)[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)N2C=C(N=C2)C2CC2)=C1 CWZONKSGCPUCFJ-AWEZNQCLSA-N 0.000 claims 2
- OHYKJIGILBYHKC-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 OHYKJIGILBYHKC-UHFFFAOYSA-N 0.000 claims 2
- XDUJYPJVBLAJKJ-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 XDUJYPJVBLAJKJ-UHFFFAOYSA-N 0.000 claims 2
- UIQLWDNHZZPCHD-UHFFFAOYSA-N 4-chloro-5-(6-cyclopropylpyridin-3-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-2-fluorobenzamide Chemical compound FC1=CC(Cl)=C(C=2C=NC(=CC=2)C2CC2)C=C1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 UIQLWDNHZZPCHD-UHFFFAOYSA-N 0.000 claims 2
- PRHILGIXJLEDBO-UHFFFAOYSA-N 6-(6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C=CC(C=2C=NC(=CC=2)C2CC2)=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 PRHILGIXJLEDBO-UHFFFAOYSA-N 0.000 claims 2
- 229940127254 ASK1 inhibitor Drugs 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- XXOBJQOBXLLMMT-UHFFFAOYSA-N C1(CC1)N1C(=NN=C1)C1=CC=CC(=N1)N1C(C=C(C=C1)N1C=NC(=C1C)C)C Chemical compound C1(CC1)N1C(=NN=C1)C1=CC=CC(=N1)N1C(C=C(C=C1)N1C=NC(=C1C)C)C XXOBJQOBXLLMMT-UHFFFAOYSA-N 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- OPARQLUIZUMIQR-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[5-methyl-4-(trifluoromethyl)-6,7-dihydro-4h-imidazo[4,5-c]pyridin-1-yl]pyridine-2-carboxamide Chemical compound FC(F)(F)C1N(C)CCC2=C1N=CN2C(C=1)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 OPARQLUIZUMIQR-UHFFFAOYSA-N 0.000 claims 2
- KWOXVXDOTCOBNJ-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(2,2,2-trifluoroethyl)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(CC(F)(F)F)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 KWOXVXDOTCOBNJ-UHFFFAOYSA-N 0.000 claims 2
- HXMHZJPPAYHFEW-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-3-quinolin-3-ylbenzamide Chemical compound C=1C=CC(C=2C=C3C=CC=CC3=NC=2)=CC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 HXMHZJPPAYHFEW-UHFFFAOYSA-N 0.000 claims 2
- JDUSJBULPNMZIP-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(C)(O)C)=CC=C1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 JDUSJBULPNMZIP-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims 2
- UYURQXWMXAOMBK-UHFFFAOYSA-N 1-[3-[[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]carbamoyl]phenyl]-5-methylimidazole-4-carboxylic acid Chemical compound CC1=C(C(O)=O)N=CN1C1=CC=CC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 UYURQXWMXAOMBK-UHFFFAOYSA-N 0.000 claims 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 1
- PWRAOHMWIGDSPU-UHFFFAOYSA-N 2-(6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-4-carboxamide Chemical compound C=1C=NC(C=2C=NC(=CC=2)C2CC2)=CC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 PWRAOHMWIGDSPU-UHFFFAOYSA-N 0.000 claims 1
- ANEKNGXSOTWRDL-UHFFFAOYSA-N 2-(6-cyclopropylpyridin-3-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]pyridine-4-carboxamide Chemical compound C=1C=NC(C=2C=NC(=CC=2)C2CC2)=CC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 ANEKNGXSOTWRDL-UHFFFAOYSA-N 0.000 claims 1
- ORYZBUNRYCVWJA-UHFFFAOYSA-N 3-(4-cyclopropylimidazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-2-methylbenzamide Chemical compound CC1=C(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)C=CC=C1N(C=1)C=NC=1C1CC1 ORYZBUNRYCVWJA-UHFFFAOYSA-N 0.000 claims 1
- CLWNEOXYSGKKIM-UHFFFAOYSA-N 3-(4-cyclopropylimidazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-methoxybenzamide Chemical compound COC1=CC=C(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)C=C1N(C=1)C=NC=1C1CC1 CLWNEOXYSGKKIM-UHFFFAOYSA-N 0.000 claims 1
- QHAUPWYENQTMNO-UHFFFAOYSA-N 3-(4-cyclopropylimidazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)C=C1N(C=1)C=NC=1C1CC1 QHAUPWYENQTMNO-UHFFFAOYSA-N 0.000 claims 1
- SVYPENLGHUOCQD-UHFFFAOYSA-N 3-(4-cyclopropylimidazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-5-fluorobenzamide Chemical compound C=1C(F)=CC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=CC=1N(C=1)C=NC=1C1CC1 SVYPENLGHUOCQD-UHFFFAOYSA-N 0.000 claims 1
- ZRGFHFVCJIZWJJ-UHFFFAOYSA-N 3-(4-cyclopropylimidazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-5-methylbenzamide Chemical compound C=1C(C)=CC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=CC=1N(C=1)C=NC=1C1CC1 ZRGFHFVCJIZWJJ-UHFFFAOYSA-N 0.000 claims 1
- JFRSLEBBTJAYKT-UHFFFAOYSA-N 3-(4-cyclopropylimidazol-1-yl)-n-[6-(4-propan-2-yl-1,2,4-triazol-3-yl)pyridin-2-yl]benzamide Chemical compound CC(C)N1C=NN=C1C1=CC=CC(NC(=O)C=2C=C(C=CC=2)N2C=C(N=C2)C2CC2)=N1 JFRSLEBBTJAYKT-UHFFFAOYSA-N 0.000 claims 1
- SJKYOXDWFILZJJ-UHFFFAOYSA-N 3-(6-cyclopropylpyridin-3-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]benzamide Chemical compound C=1C=CC(C=2C=NC(=CC=2)C2CC2)=CC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 SJKYOXDWFILZJJ-UHFFFAOYSA-N 0.000 claims 1
- OPVNUCOTCYNSIT-UHFFFAOYSA-N 4-(2-aminopyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound NC1=NC=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 OPVNUCOTCYNSIT-UHFFFAOYSA-N 0.000 claims 1
- WBEYBRYJAQKIBV-UHFFFAOYSA-N 4-(2-aminopyrimidin-5-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C1=NC(N)=NC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 WBEYBRYJAQKIBV-UHFFFAOYSA-N 0.000 claims 1
- ZLXNFEXYBUQYRS-UHFFFAOYSA-N 4-(3-aminopyrrolidin-1-yl)-n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)N2CC(N)CC2)=C1 ZLXNFEXYBUQYRS-UHFFFAOYSA-N 0.000 claims 1
- VDHWXRVYARKNEN-UHFFFAOYSA-N 4-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2ON=C(N=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 VDHWXRVYARKNEN-UHFFFAOYSA-N 0.000 claims 1
- YHJZYWIEDZFZTC-UHFFFAOYSA-N 4-(3-cyclopropyl-1,2,4-triazol-1-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(N2N=C(N=C2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 YHJZYWIEDZFZTC-UHFFFAOYSA-N 0.000 claims 1
- ATWVMVICZNEPIS-UHFFFAOYSA-N 4-(3-methylimidazol-4-yl)-n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound CN1C=NC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C)=C1 ATWVMVICZNEPIS-UHFFFAOYSA-N 0.000 claims 1
- COAIOYUZIYDHHI-UHFFFAOYSA-N 4-(4-chloroimidazol-1-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C1=NC(Cl)=CN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 COAIOYUZIYDHHI-UHFFFAOYSA-N 0.000 claims 1
- PVPSFOMUSUJVJD-UHFFFAOYSA-N 4-(4-cyclopropyl-2-methylimidazol-1-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound CC1=NC(C2CC2)=CN1C(C=1)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 PVPSFOMUSUJVJD-UHFFFAOYSA-N 0.000 claims 1
- DDZYGVDJIIXACJ-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-2-methyl-1-[3-(4-pyridin-2-yl-1,2,4-triazol-3-yl)phenyl]-2H-pyridine Chemical compound C1(CC1)C=1N=CN(C=1)C1=CC(N(C=C1)C1=CC(=CC=C1)C1=NN=CN1C1=NC=CC=C1)C DDZYGVDJIIXACJ-UHFFFAOYSA-N 0.000 claims 1
- UIZCAIJJBDQQHD-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[3-(4-propan-2-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound CC(C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)N2C=C(N=C2)C2CC2)=C1 UIZCAIJJBDQQHD-UHFFFAOYSA-N 0.000 claims 1
- VJOPVYDEOJCVGW-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[3-[4-(1-phenylethyl)-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound C1=NN=C(C=2C=C(NC(=O)C=3N=CC=C(C=3)N3C=C(N=C3)C3CC3)C=CC=2)N1C(C)C1=CC=CC=C1 VJOPVYDEOJCVGW-UHFFFAOYSA-N 0.000 claims 1
- LSEDGIXFBSWZKL-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[3-[4-(cyclopropylmethyl)-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound C=1C(N2C=C(N=C2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1CC1CC1 LSEDGIXFBSWZKL-UHFFFAOYSA-N 0.000 claims 1
- KMWDQIUOZZDYRN-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]pyridine-2-carboxamide Chemical compound C=1C(N2C=C(N=C2)C2CC2)=CC=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 KMWDQIUOZZDYRN-UHFFFAOYSA-N 0.000 claims 1
- TVDPMASDODMCGQ-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]quinoline-2-carboxamide Chemical compound C=1C(N2C=C(N=C2)C2CC2)=C2C=CC=CC2=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 TVDPMASDODMCGQ-UHFFFAOYSA-N 0.000 claims 1
- DLKPXPZUVSZPGK-UHFFFAOYSA-N 4-(4-cyclopropylphenyl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=CC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 DLKPXPZUVSZPGK-UHFFFAOYSA-N 0.000 claims 1
- KBRLQVBGSCHYKI-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)-n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C1CN(C)CCN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C)=C1 KBRLQVBGSCHYKI-UHFFFAOYSA-N 0.000 claims 1
- HNYNGXKHKFGVBR-UHFFFAOYSA-N 4-(5-chloro-6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound ClC1=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=CN=C1C1CC1 HNYNGXKHKFGVBR-UHFFFAOYSA-N 0.000 claims 1
- XMIDMDWLWJGOJO-UHFFFAOYSA-N 4-(5-chloro-6-ethylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C1=C(Cl)C(CC)=NC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 XMIDMDWLWJGOJO-UHFFFAOYSA-N 0.000 claims 1
- PPJNKMGNBFLTBW-UHFFFAOYSA-N 4-(5-chloropyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound ClC1=CN=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 PPJNKMGNBFLTBW-UHFFFAOYSA-N 0.000 claims 1
- MPPHLNGBNOKFMV-UHFFFAOYSA-N 4-(5-cyanopyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=C(C=NC=2)C#N)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 MPPHLNGBNOKFMV-UHFFFAOYSA-N 0.000 claims 1
- NGSRPODQIQEEMR-UHFFFAOYSA-N 4-(5-cyclopropyl-1,2,4-triazol-1-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(N2C(=NC=N2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 NGSRPODQIQEEMR-UHFFFAOYSA-N 0.000 claims 1
- CZIUEMXDLQZYGK-UHFFFAOYSA-N 4-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2SC(=NN=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 CZIUEMXDLQZYGK-UHFFFAOYSA-N 0.000 claims 1
- RLGFHCROFVRTAF-UHFFFAOYSA-N 4-(5-cyclopropylpyrazin-2-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2N=CC(=NC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 RLGFHCROFVRTAF-UHFFFAOYSA-N 0.000 claims 1
- HZRLUTSOXHJXOK-UHFFFAOYSA-N 4-(5-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=C(C=NC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 HZRLUTSOXHJXOK-UHFFFAOYSA-N 0.000 claims 1
- IFASTQOSKKEWDD-UHFFFAOYSA-N 4-(5-methoxypyridin-3-yl)-n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound COC1=CN=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C)=C1 IFASTQOSKKEWDD-UHFFFAOYSA-N 0.000 claims 1
- QXPYZSBTIUATJG-UHFFFAOYSA-N 4-(6-aminopyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C1=NC(N)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 QXPYZSBTIUATJG-UHFFFAOYSA-N 0.000 claims 1
- BDFOJJBACAFICD-UHFFFAOYSA-N 4-(6-cyclobutyloxypyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(OC3CCC3)=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 BDFOJJBACAFICD-UHFFFAOYSA-N 0.000 claims 1
- FDGVSBVOFQXYQJ-UHFFFAOYSA-N 4-(6-cyclobutylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CCC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 FDGVSBVOFQXYQJ-UHFFFAOYSA-N 0.000 claims 1
- JDCRZLPHKMOKSG-UHFFFAOYSA-N 4-(6-cyclopentylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CCCC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 JDCRZLPHKMOKSG-UHFFFAOYSA-N 0.000 claims 1
- IDDSYESOBQTNGY-UHFFFAOYSA-N 4-(6-cyclopropyl-5-fluoropyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound FC1=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=CN=C1C1CC1 IDDSYESOBQTNGY-UHFFFAOYSA-N 0.000 claims 1
- KDAQKBWZTUGFQY-UHFFFAOYSA-N 4-(6-cyclopropyloxypyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(OC3CC3)=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 KDAQKBWZTUGFQY-UHFFFAOYSA-N 0.000 claims 1
- HEQPLJOZGXWHRJ-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-4-yl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=NC=1C1=NN=CN1C1CC1 HEQPLJOZGXWHRJ-UHFFFAOYSA-N 0.000 claims 1
- JCGCGDWQFBXIFS-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)-2-fluorophenyl]pyridine-2-carboxamide Chemical compound C1=CC=C(C=2N(C=NN=2)C2CC2)C(F)=C1NC(=O)C(N=CC=1)=CC=1C(C=N1)=CC=C1C1CC1 JCGCGDWQFBXIFS-UHFFFAOYSA-N 0.000 claims 1
- ZWUQCUNTWFRCNU-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)-4-fluorophenyl]pyridine-2-carboxamide Chemical compound C1=C(C=2N(C=NN=2)C2CC2)C(F)=CC=C1NC(=O)C(N=CC=1)=CC=1C(C=N1)=CC=C1C1CC1 ZWUQCUNTWFRCNU-UHFFFAOYSA-N 0.000 claims 1
- OSWJOKQOVKCHDS-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)-5-fluorophenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2N(C=NN=2)C2CC2)=CC(F)=CC=1NC(=O)C(N=CC=1)=CC=1C(C=N1)=CC=C1C1CC1 OSWJOKQOVKCHDS-UHFFFAOYSA-N 0.000 claims 1
- HQMYIKNYYOEUJH-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-5-methylpyridine-2-carboxamide Chemical compound CC1=CN=C(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)C=C1C(C=N1)=CC=C1C1CC1 HQMYIKNYYOEUJH-UHFFFAOYSA-N 0.000 claims 1
- PZAFLBLEILTJLN-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-6-methylpyridine-2-carboxamide Chemical compound N=1C(C)=CC(C=2C=NC(=CC=2)C2CC2)=CC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 PZAFLBLEILTJLN-UHFFFAOYSA-N 0.000 claims 1
- XQPSTZRYCDCPTJ-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-pentan-3-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound CCC(CC)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 XQPSTZRYCDCPTJ-UHFFFAOYSA-N 0.000 claims 1
- PQMGWGOFVWECKF-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-phenyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1=CC=CC=C1 PQMGWGOFVWECKF-UHFFFAOYSA-N 0.000 claims 1
- VDXZIYAQWPGUPS-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-propan-2-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound CC(C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 VDXZIYAQWPGUPS-UHFFFAOYSA-N 0.000 claims 1
- INTURJDUCNJHIF-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-pyridin-2-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1=CC=CC=N1 INTURJDUCNJHIF-UHFFFAOYSA-N 0.000 claims 1
- LCKILEVPLUIPKT-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-pyridin-3-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1=CC=CN=C1 LCKILEVPLUIPKT-UHFFFAOYSA-N 0.000 claims 1
- UPJTWKYDWVAZPN-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-pyridin-4-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1=CC=NC=C1 UPJTWKYDWVAZPN-UHFFFAOYSA-N 0.000 claims 1
- PTGTWYUFALWBHL-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-pyrimidin-5-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1=CN=CN=C1 PTGTWYUFALWBHL-UHFFFAOYSA-N 0.000 claims 1
- GORYCFWKSUNYCW-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-[4-(1-pyridin-3-yloxypropan-2-yl)-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound C1=NN=C(C=2C=C(NC(=O)C=3N=CC=C(C=3)C=3C=NC(=CC=3)C3CC3)C=CC=2)N1C(C)COC1=CC=CN=C1 GORYCFWKSUNYCW-UHFFFAOYSA-N 0.000 claims 1
- NZVFKCPECCNKPL-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-[4-(2-phenylcyclopropyl)-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1C1=CC=CC=C1 NZVFKCPECCNKPL-UHFFFAOYSA-N 0.000 claims 1
- WHDVUGOEWSJVPZ-HSZRJFAPSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-[4-[(2r)-1-(2,6-dimethylphenoxy)propan-2-yl]-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound C([C@@H](C)N1C(=NN=C1)C=1C=C(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)C=CC=1)OC1=C(C)C=CC=C1C WHDVUGOEWSJVPZ-HSZRJFAPSA-N 0.000 claims 1
- VWUVSQBHGIBXRT-HNNXBMFYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-[4-[(2s)-1,1,1-trifluoropropan-2-yl]-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound FC(F)(F)[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 VWUVSQBHGIBXRT-HNNXBMFYSA-N 0.000 claims 1
- VRBJAMNRLJKDBF-KRWDZBQOSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-[4-[(2s)-1-methoxypropan-2-yl]-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound COC[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 VRBJAMNRLJKDBF-KRWDZBQOSA-N 0.000 claims 1
- TYFCBULBGOMMNM-SFHVURJKSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-[4-[(2s)-3,3-dimethylbutan-2-yl]-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound CC(C)(C)[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 TYFCBULBGOMMNM-SFHVURJKSA-N 0.000 claims 1
- FXNORAMBZTUWTL-SFHVURJKSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-[4-[(2s)-3-methylbutan-2-yl]-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound CC(C)[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 FXNORAMBZTUWTL-SFHVURJKSA-N 0.000 claims 1
- MFEGGOYIQWZCMZ-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-[4-[1-(2,2,2-trifluoroethoxy)propan-2-yl]-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound FC(F)(F)COCC(C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 MFEGGOYIQWZCMZ-UHFFFAOYSA-N 0.000 claims 1
- HXYAABYWDBLUKS-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-5-methylpyridine-2-carboxamide Chemical compound CC1=CN=C(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)C=C1C(C=N1)=CC=C1C1CC1 HXYAABYWDBLUKS-UHFFFAOYSA-N 0.000 claims 1
- DEOJOKGSDYNDJQ-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-7,8-dimethylquinoline-2-carboxamide Chemical compound N=1C2=C(C)C(C)=CC=C2C(C=2C=NC(=CC=2)C2CC2)=CC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 DEOJOKGSDYNDJQ-UHFFFAOYSA-N 0.000 claims 1
- WEQUSOAFGUTBRD-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]quinoline-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=C2C=CC=CC2=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 WEQUSOAFGUTBRD-UHFFFAOYSA-N 0.000 claims 1
- IGQVVOYLYKCVIZ-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[6-(4-propan-2-yl-1,2,4-triazol-3-yl)pyridin-2-yl]pyridine-2-carboxamide Chemical compound CC(C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=N1 IGQVVOYLYKCVIZ-UHFFFAOYSA-N 0.000 claims 1
- JFLVKJCZAVMEAA-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[6-[4-(1-pyrrolidin-1-ylpropan-2-yl)-1,2,4-triazol-3-yl]pyridin-2-yl]pyridine-2-carboxamide Chemical compound C1=NN=C(C=2N=C(NC(=O)C=3N=CC=C(C=3)C=3C=NC(=CC=3)C3CC3)C=CC=2)N1C(C)CN1CCCC1 JFLVKJCZAVMEAA-UHFFFAOYSA-N 0.000 claims 1
- MXYHSDMJCZGCDL-AAFJCEBUSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[6-[4-[(2r)-3-hydroxybutan-2-yl]-1,2,4-triazol-3-yl]pyridin-2-yl]pyridine-2-carboxamide Chemical compound CC(O)[C@@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=N1 MXYHSDMJCZGCDL-AAFJCEBUSA-N 0.000 claims 1
- MXYHSDMJCZGCDL-JKSUJKDBSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[6-[4-[(2s,3r)-3-hydroxybutan-2-yl]-1,2,4-triazol-3-yl]pyridin-2-yl]pyridine-2-carboxamide Chemical compound C[C@@H](O)[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=N1 MXYHSDMJCZGCDL-JKSUJKDBSA-N 0.000 claims 1
- MXYHSDMJCZGCDL-HOTGVXAUSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[6-[4-[(2s,3s)-3-hydroxybutan-2-yl]-1,2,4-triazol-3-yl]pyridin-2-yl]pyridine-2-carboxamide Chemical compound C[C@H](O)[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=N1 MXYHSDMJCZGCDL-HOTGVXAUSA-N 0.000 claims 1
- HTLNKQRNTPZZPF-UHFFFAOYSA-N 4-(6-tert-butylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C1=NC(C(C)(C)C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 HTLNKQRNTPZZPF-UHFFFAOYSA-N 0.000 claims 1
- RHTBEYULLGYGIC-UHFFFAOYSA-N 4-(benzimidazol-1-yl)-n-[3-(3-cyclopropylimidazol-4-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(N2C3=CC=CC=C3N=C2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=CN=CN1C1CC1 RHTBEYULLGYGIC-UHFFFAOYSA-N 0.000 claims 1
- QYNIPIQABZPLGE-UHFFFAOYSA-N 4-(benzimidazol-1-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(N2C3=CC=CC=C3N=C2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 QYNIPIQABZPLGE-UHFFFAOYSA-N 0.000 claims 1
- HYJLJPAFUKVVIP-UHFFFAOYSA-N 4-(benzotriazol-1-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(N2C3=CC=CC=C3N=N2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 HYJLJPAFUKVVIP-UHFFFAOYSA-N 0.000 claims 1
- YMVHVUXATZHVLX-UHFFFAOYSA-N 4-[4-(cyclopropylsulfamoyl)phenyl]-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=CC(=CC=2)S(=O)(=O)NC2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 YMVHVUXATZHVLX-UHFFFAOYSA-N 0.000 claims 1
- PZHAJKQCOKCKIS-UHFFFAOYSA-N 4-[6-(cyclopropylamino)pyridin-3-yl]-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(NC3CC3)=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 PZHAJKQCOKCKIS-UHFFFAOYSA-N 0.000 claims 1
- JYWXDSFQZPJKKN-UHFFFAOYSA-N 4-[6-(cyclopropylmethyl)pyridin-3-yl]-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(CC3CC3)=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 JYWXDSFQZPJKKN-UHFFFAOYSA-N 0.000 claims 1
- FTZBXWOSEDDENS-UHFFFAOYSA-N 4-imidazo[1,2-a]pyridin-3-yl-n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2N3C=CC=CC3=NC=2)=C1 FTZBXWOSEDDENS-UHFFFAOYSA-N 0.000 claims 1
- DPIAFQOMVXIMSB-UHFFFAOYSA-N 4-pyridin-3-yl-n-[3-[4-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound FC(F)(F)CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC=CC=2)=C1 DPIAFQOMVXIMSB-UHFFFAOYSA-N 0.000 claims 1
- LMBGTCSOQZKXEM-AWEZNQCLSA-N 4-pyridin-3-yl-n-[3-[4-[(2s)-1,1,1-trifluoropropan-2-yl]-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound FC(F)(F)[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC=CC=2)=C1 LMBGTCSOQZKXEM-AWEZNQCLSA-N 0.000 claims 1
- FEBHPRFFYKZXST-UHFFFAOYSA-N 5-(2,5-difluorophenyl)-n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]pyridine-3-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2C=C(C=NC=2)C=2C(=CC=C(F)C=2)F)=C1 FEBHPRFFYKZXST-UHFFFAOYSA-N 0.000 claims 1
- HBAWHKLKYGOHCQ-UHFFFAOYSA-N 5-(4-cyclopropylimidazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-2-methylbenzamide Chemical compound CC1=CC=C(N2C=C(N=C2)C2CC2)C=C1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 HBAWHKLKYGOHCQ-UHFFFAOYSA-N 0.000 claims 1
- BORMTGVNZUGOQG-UHFFFAOYSA-N 5-(6-cyclopropylpyridin-3-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-2-fluorobenzamide Chemical compound FC1=CC=C(C=2C=NC(=CC=2)C2CC2)C=C1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 BORMTGVNZUGOQG-UHFFFAOYSA-N 0.000 claims 1
- JBEVHMTXTNJMDU-UHFFFAOYSA-N 6-(6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyrimidine-4-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=NC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 JBEVHMTXTNJMDU-UHFFFAOYSA-N 0.000 claims 1
- RNJXHBRLBNFYOM-UHFFFAOYSA-N 6-(6-cyclopropylpyridin-3-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]pyridine-2-carboxamide Chemical compound C=1C=CC(C=2C=NC(=CC=2)C2CC2)=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 RNJXHBRLBNFYOM-UHFFFAOYSA-N 0.000 claims 1
- GUEXQAKJUQJTQH-UHFFFAOYSA-N 6-methyl-n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound N=1C(C)=CC(C=2C=NC=CC=2)=CC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C GUEXQAKJUQJTQH-UHFFFAOYSA-N 0.000 claims 1
- SPVLPRBOXBUXMO-UHFFFAOYSA-N 6-phenylpyrimidine-4-carboxamide Chemical compound C1=NC(C(=O)N)=CC(C=2C=CC=CC=2)=N1 SPVLPRBOXBUXMO-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- NRXQFRCTOHZEOV-UHFFFAOYSA-N C(C#CC)N1C(=NN=C1)C=1C=C(C=CC1)N1C(C=C(C=C1)N1C=NC(=C1)C1CC1)C Chemical compound C(C#CC)N1C(=NN=C1)C=1C=C(C=CC1)N1C(C=C(C=C1)N1C=NC(=C1)C1CC1)C NRXQFRCTOHZEOV-UHFFFAOYSA-N 0.000 claims 1
- LITLMJUIPYBRSN-UHFFFAOYSA-N C1(CC1)C=1N=CN(C1)C1=CC(N(C=C1)C1=CC(=CC=C1)C1=NN=CN1C1=CC=NC=C1)C Chemical compound C1(CC1)C=1N=CN(C1)C1=CC(N(C=C1)C1=CC(=CC=C1)C1=NN=CN1C1=CC=NC=C1)C LITLMJUIPYBRSN-UHFFFAOYSA-N 0.000 claims 1
- NUUBOKAHDNRYON-UHFFFAOYSA-N C1(CC1)C=1N=CN(C1)C1=CC(N(C=C1)C1=CC(=CC=C1)C1=NN=CN1C=1C=NC=CC1)C Chemical compound C1(CC1)C=1N=CN(C1)C1=CC(N(C=C1)C1=CC(=CC=C1)C1=NN=CN1C=1C=NC=CC1)C NUUBOKAHDNRYON-UHFFFAOYSA-N 0.000 claims 1
- SXOOPSZRFLJDNX-UHFFFAOYSA-N C1(CC1)C=1N=CN(C1)C1=CC(N(C=C1)C1=CC(=CC=C1)C1=NN=CN1C=1C=NC=NC1)C Chemical compound C1(CC1)C=1N=CN(C1)C1=CC(N(C=C1)C1=CC(=CC=C1)C1=NN=CN1C=1C=NC=NC1)C SXOOPSZRFLJDNX-UHFFFAOYSA-N 0.000 claims 1
- VQXLKYHRNFSFEX-UHFFFAOYSA-N C1(CC1)N1C(=NN=C1)C=1C=C(C=CC1)N1C(C=C(C=C1)C1=NC(=NO1)C)C Chemical compound C1(CC1)N1C(=NN=C1)C=1C=C(C=CC1)N1C(C=C(C=C1)C1=NC(=NO1)C)C VQXLKYHRNFSFEX-UHFFFAOYSA-N 0.000 claims 1
- PYPBWBSDWQWFQU-DGMVEDKYSA-N C1(CC1)N1C(=NN=C1)C=1C=C(C=CC1)NC(=O)C1=NC=CC(=C1)C=1C(=NC=CC1)OC.C[C@@H]1[C@H](C1)N1C(=NN=C1)C=1C=C(C=CC1)NC(=O)C1=NC=CC(=C1)C=1C=NC=CC1 Chemical compound C1(CC1)N1C(=NN=C1)C=1C=C(C=CC1)NC(=O)C1=NC=CC(=C1)C=1C(=NC=CC1)OC.C[C@@H]1[C@H](C1)N1C(=NN=C1)C=1C=C(C=CC1)NC(=O)C1=NC=CC(=C1)C=1C=NC=CC1 PYPBWBSDWQWFQU-DGMVEDKYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- LFVGNYGYHAHJOC-UHFFFAOYSA-N methyl n-[5-[2-[[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]carbamoyl]pyridin-4-yl]pyridin-2-yl]carbamate Chemical compound C1=NC(NC(=O)OC)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 LFVGNYGYHAHJOC-UHFFFAOYSA-N 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- LOPBPYGKLPLRMH-UHFFFAOYSA-N n-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-4-yl]-4-quinolin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=C3C=CC=CC3=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=NC=1C1=NN=CN1C1CC1 LOPBPYGKLPLRMH-UHFFFAOYSA-N 0.000 claims 1
- ZSIVCFPTLSXLTH-UHFFFAOYSA-N n-[3-(3-cyclopropylimidazol-4-yl)phenyl]-4-(6-cyclopropylpyridin-3-yl)pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=CN=CN1C1CC1 ZSIVCFPTLSXLTH-UHFFFAOYSA-N 0.000 claims 1
- SOSKKYYLWDMZID-UHFFFAOYSA-N n-[3-(3-cyclopropylimidazol-4-yl)phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=NC=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=CN=CN1C1CC1 SOSKKYYLWDMZID-UHFFFAOYSA-N 0.000 claims 1
- YKZKDUCYZYVDOM-UHFFFAOYSA-N n-[3-(4-but-2-ynyl-1,2,4-triazol-3-yl)phenyl]-4-(6-cyclopropylpyridin-3-yl)pyridine-2-carboxamide Chemical compound CC#CCN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 YKZKDUCYZYVDOM-UHFFFAOYSA-N 0.000 claims 1
- ZYYCJXOQDWDLGN-UHFFFAOYSA-N n-[3-(4-butan-2-yl-1,2,4-triazol-3-yl)phenyl]-4-(6-cyclopropylpyridin-3-yl)pyridine-2-carboxamide Chemical compound CCC(C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 ZYYCJXOQDWDLGN-UHFFFAOYSA-N 0.000 claims 1
- AOSNBVFWJSGSEZ-UHFFFAOYSA-N n-[3-(4-cyclobutyl-1,2,4-triazol-3-yl)phenyl]-4-(6-cyclopropylpyridin-3-yl)pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CCC1 AOSNBVFWJSGSEZ-UHFFFAOYSA-N 0.000 claims 1
- XXESGZXHEMVWTN-UHFFFAOYSA-N n-[3-(4-cyclobutyl-1,2,4-triazol-3-yl)phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=NC=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CCC1 XXESGZXHEMVWTN-UHFFFAOYSA-N 0.000 claims 1
- PRGDOHNQSPEJFW-UHFFFAOYSA-N n-[3-(4-cyclopentyl-1,2,4-triazol-3-yl)phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=NC=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CCCC1 PRGDOHNQSPEJFW-UHFFFAOYSA-N 0.000 claims 1
- UZIRCFXJGVIITM-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)-2-fluorophenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C1=CC=C(C=2N(C=NN=2)C2CC2)C(F)=C1NC(=O)C(N=CC=1)=CC=1C1=CC=CN=C1 UZIRCFXJGVIITM-UHFFFAOYSA-N 0.000 claims 1
- JWVQUGPQDBPPKO-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)-4-fluorophenyl]-4-(6-ethylpyridin-3-yl)pyridine-2-carboxamide Chemical compound C1=NC(CC)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C(F)=CC=2)C=2N(C=NN=2)C2CC2)=C1 JWVQUGPQDBPPKO-UHFFFAOYSA-N 0.000 claims 1
- ZTXCAYUULVSBRA-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)-5-fluorophenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2N(C=NN=2)C2CC2)=CC(F)=CC=1NC(=O)C(N=CC=1)=CC=1C1=CC=CN=C1 ZTXCAYUULVSBRA-UHFFFAOYSA-N 0.000 claims 1
- KTYYSBXAPOFXOE-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(1,2,4-triazol-1-yl)pyridine-2-carboxamide Chemical compound C=1C(N2N=CN=C2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 KTYYSBXAPOFXOE-UHFFFAOYSA-N 0.000 claims 1
- NHZFWJSZZBCCBF-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(1,5-dimethylpyrazol-4-yl)pyridine-2-carboxamide Chemical compound C1=NN(C)C(C)=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 NHZFWJSZZBCCBF-UHFFFAOYSA-N 0.000 claims 1
- VZJUODFTXTXAHM-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(1,5-naphthyridin-3-yl)pyridine-2-carboxamide Chemical compound C=1C(C=2C=C3N=CC=CC3=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 VZJUODFTXTXAHM-UHFFFAOYSA-N 0.000 claims 1
- LCOUIACXSYVITE-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(1-methylpyrazol-4-yl)pyridine-2-carboxamide Chemical compound C1=NN(C)C=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 LCOUIACXSYVITE-UHFFFAOYSA-N 0.000 claims 1
- UDFRABUCTSRYSZ-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(1-propan-2-ylpyrrolo[3,2-b]pyridin-6-yl)pyridine-2-carboxamide Chemical compound C1=C2N(C(C)C)C=CC2=NC=C1C(C=1)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 UDFRABUCTSRYSZ-UHFFFAOYSA-N 0.000 claims 1
- JPMSYGDPZSKASB-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(1h-pyrrolo[2,3-b]pyridin-5-yl)pyridine-2-carboxamide Chemical compound C=1C(C=2C=C3C=CNC3=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 JPMSYGDPZSKASB-UHFFFAOYSA-N 0.000 claims 1
- BAWOUFGKEDURTL-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(1h-pyrrolo[3,2-b]pyridin-6-yl)pyridine-2-carboxamide Chemical compound C=1C(C=2C=C3NC=CC3=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 BAWOUFGKEDURTL-UHFFFAOYSA-N 0.000 claims 1
- ZLQWOOSBLKFTJK-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(2,3-dimethylimidazol-4-yl)pyridine-2-carboxamide Chemical compound CN1C(C)=NC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 ZLQWOOSBLKFTJK-UHFFFAOYSA-N 0.000 claims 1
- VDSUJHZINKZQFH-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(2,4-dimethoxypyrimidin-5-yl)pyridine-2-carboxamide Chemical compound COC1=NC(OC)=NC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 VDSUJHZINKZQFH-UHFFFAOYSA-N 0.000 claims 1
- YUAWMUJLIUFTFM-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(2-ethylpyrimidin-5-yl)pyridine-2-carboxamide Chemical compound C1=NC(CC)=NC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 YUAWMUJLIUFTFM-UHFFFAOYSA-N 0.000 claims 1
- NVEXBDJERAOQLO-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(2-methoxypyrimidin-5-yl)pyridine-2-carboxamide Chemical compound C1=NC(OC)=NC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 NVEXBDJERAOQLO-UHFFFAOYSA-N 0.000 claims 1
- DGIZSTIXCJVKRY-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(2-methylimidazol-1-yl)pyridine-2-carboxamide Chemical compound CC1=NC=CN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 DGIZSTIXCJVKRY-UHFFFAOYSA-N 0.000 claims 1
- LVYXHGMOOUZRJN-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(2-methylpyridin-3-yl)pyridine-2-carboxamide Chemical compound CC1=NC=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 LVYXHGMOOUZRJN-UHFFFAOYSA-N 0.000 claims 1
- LWFKSPOALPOTNO-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(2-methylsulfonylphenyl)pyridine-2-carboxamide Chemical compound CS(=O)(=O)C1=CC=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 LWFKSPOALPOTNO-UHFFFAOYSA-N 0.000 claims 1
- PIMFXZURRLLXDI-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(3-hydroxypiperidin-1-yl)pyridine-2-carboxamide Chemical compound C1C(O)CCCN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 PIMFXZURRLLXDI-UHFFFAOYSA-N 0.000 claims 1
- BXCHQPREKDUPMH-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(3-methyl-2-phenylimidazol-4-yl)pyridine-2-carboxamide Chemical compound CN1C(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=CN=C1C1=CC=CC=C1 BXCHQPREKDUPMH-UHFFFAOYSA-N 0.000 claims 1
- TVRKVVFRMWPLMZ-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(3-methylimidazo[4,5-b]pyridin-6-yl)pyridine-2-carboxamide Chemical compound C=1N=C2N(C)C=NC2=CC=1C(C=1)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 TVRKVVFRMWPLMZ-UHFFFAOYSA-N 0.000 claims 1
- XKEAFANWKQKVSQ-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(3-methylimidazol-4-yl)pyridine-2-carboxamide Chemical compound CN1C=NC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 XKEAFANWKQKVSQ-UHFFFAOYSA-N 0.000 claims 1
- NADWNJBMCHMGNU-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(3-methylsulfonylphenyl)pyridine-2-carboxamide Chemical compound CS(=O)(=O)C1=CC=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 NADWNJBMCHMGNU-UHFFFAOYSA-N 0.000 claims 1
- MXTLRGXDTZELPI-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4,5-dimethylimidazol-1-yl)pyridine-2-carboxamide Chemical compound CC1=C(C)N=CN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 MXTLRGXDTZELPI-UHFFFAOYSA-N 0.000 claims 1
- QBFIQWYNEBNHJP-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-ethyl-3-oxopiperazin-1-yl)pyridine-2-carboxamide Chemical compound C1C(=O)N(CC)CCN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 QBFIQWYNEBNHJP-UHFFFAOYSA-N 0.000 claims 1
- DGFYIMWJOWYRIQ-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-ethylimidazol-1-yl)pyridine-2-carboxamide Chemical compound C1=NC(CC)=CN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 DGFYIMWJOWYRIQ-UHFFFAOYSA-N 0.000 claims 1
- ACDWSQREDGKAFT-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-ethylsulfonylphenyl)pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 ACDWSQREDGKAFT-UHFFFAOYSA-N 0.000 claims 1
- YYJOZAHLGAHACX-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-methylimidazol-1-yl)pyridine-2-carboxamide Chemical compound C1=NC(C)=CN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 YYJOZAHLGAHACX-UHFFFAOYSA-N 0.000 claims 1
- SJPPAAGARFZWNS-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-methylpyridin-3-yl)pyridine-2-carboxamide Chemical compound CC1=CC=NC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 SJPPAAGARFZWNS-UHFFFAOYSA-N 0.000 claims 1
- YBXKCRBRCJYTKT-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-methylsulfonylphenyl)pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 YBXKCRBRCJYTKT-UHFFFAOYSA-N 0.000 claims 1
- BZBRGMWUSRCAFW-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-methylsulfonylpiperazin-1-yl)pyridine-2-carboxamide Chemical compound C1CN(S(=O)(=O)C)CCN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 BZBRGMWUSRCAFW-UHFFFAOYSA-N 0.000 claims 1
- NSBLRQRQYOPWCJ-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-propan-2-ylimidazol-1-yl)pyridine-2-carboxamide Chemical compound C1=NC(C(C)C)=CN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 NSBLRQRQYOPWCJ-UHFFFAOYSA-N 0.000 claims 1
- ZZGMGULKPVQEMW-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-propan-2-ylsulfonylphenyl)pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)C(C)C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 ZZGMGULKPVQEMW-UHFFFAOYSA-N 0.000 claims 1
- PQLJPIXGFQFBLQ-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-sulfamoylphenyl)pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 PQLJPIXGFQFBLQ-UHFFFAOYSA-N 0.000 claims 1
- MOEIRIXQBVJSDL-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)pyridine-2-carboxamide Chemical compound C=1C(C=2C=C3CNCCC3=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 MOEIRIXQBVJSDL-UHFFFAOYSA-N 0.000 claims 1
- MGNBENZAYRLHPD-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(5,6-diethylpyridin-3-yl)pyridine-2-carboxamide Chemical compound N1=C(CC)C(CC)=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 MGNBENZAYRLHPD-UHFFFAOYSA-N 0.000 claims 1
- FPHNFBWCCUYIGD-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(5-ethylpyridin-3-yl)pyridine-2-carboxamide Chemical compound CCC1=CN=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 FPHNFBWCCUYIGD-UHFFFAOYSA-N 0.000 claims 1
- APNDFXWFNYAUPK-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(5-fluoropyridin-3-yl)pyridine-2-carboxamide Chemical compound FC1=CN=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 APNDFXWFNYAUPK-UHFFFAOYSA-N 0.000 claims 1
- RKWNPZYNQWHMNW-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(5-methoxypyridin-3-yl)pyridine-2-carboxamide Chemical compound COC1=CN=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 RKWNPZYNQWHMNW-UHFFFAOYSA-N 0.000 claims 1
- SDDOJDLRNYWTLO-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-ethyl-5-fluoropyridin-3-yl)pyridine-2-carboxamide Chemical compound C1=C(F)C(CC)=NC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 SDDOJDLRNYWTLO-UHFFFAOYSA-N 0.000 claims 1
- JVULQTVUMUMRAP-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-fluoro-5-methylpyridin-3-yl)pyridine-2-carboxamide Chemical compound N1=C(F)C(C)=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 JVULQTVUMUMRAP-UHFFFAOYSA-N 0.000 claims 1
- VEIPVPSITFJJBD-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-fluoropyridin-3-yl)pyridine-2-carboxamide Chemical compound C1=NC(F)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 VEIPVPSITFJJBD-UHFFFAOYSA-N 0.000 claims 1
- OCWFSCGCBTYILD-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-methoxypyridin-3-yl)pyridine-2-carboxamide Chemical compound C1=NC(OC)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 OCWFSCGCBTYILD-UHFFFAOYSA-N 0.000 claims 1
- YGHFHYNCRXPLDS-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-methoxyquinolin-3-yl)pyridine-2-carboxamide Chemical compound C=1C2=CC(OC)=CC=C2N=CC=1C(C=1)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 YGHFHYNCRXPLDS-UHFFFAOYSA-N 0.000 claims 1
- BTZVLKJJVVPPJV-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-methylpyridin-3-yl)pyridine-2-carboxamide Chemical compound C1=NC(C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 BTZVLKJJVVPPJV-UHFFFAOYSA-N 0.000 claims 1
- ULAMEPHYFLWXOF-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-methylsulfanylpyridin-3-yl)pyridine-2-carboxamide Chemical compound C1=NC(SC)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 ULAMEPHYFLWXOF-UHFFFAOYSA-N 0.000 claims 1
- LOXGOQPJODPIND-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-oxo-1h-pyridin-3-yl)pyridine-2-carboxamide Chemical compound C1=NC(O)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 LOXGOQPJODPIND-UHFFFAOYSA-N 0.000 claims 1
- ROXITARWDFOLPR-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-propan-2-yloxypyridin-3-yl)pyridine-2-carboxamide Chemical compound C1=NC(OC(C)C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 ROXITARWDFOLPR-UHFFFAOYSA-N 0.000 claims 1
- KKPWBZLVANVAJH-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-propan-2-ylpyridin-3-yl)pyridine-2-carboxamide Chemical compound C1=NC(C(C)C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 KKPWBZLVANVAJH-UHFFFAOYSA-N 0.000 claims 1
- QDYWHKKQBLXWBA-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-propylpyridin-3-yl)pyridine-2-carboxamide Chemical compound C1=NC(CCC)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 QDYWHKKQBLXWBA-UHFFFAOYSA-N 0.000 claims 1
- PTMFZWYUDDQMDS-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-pyrrolidin-1-ylpyridin-3-yl)pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)N2CCCC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 PTMFZWYUDDQMDS-UHFFFAOYSA-N 0.000 claims 1
- FMODEHMEPLTKHQ-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[1-(2,2,2-trifluoroethyl)pyrrolo[3,2-b]pyridin-6-yl]pyridine-2-carboxamide Chemical compound C1=C2N(CC(F)(F)F)C=CC2=NC=C1C(C=1)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 FMODEHMEPLTKHQ-UHFFFAOYSA-N 0.000 claims 1
- IMIYTEJJZKVFNR-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[4-(2,2,2-trifluoro-1-hydroxyethyl)imidazol-1-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(O)C(F)(F)F)=CN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 IMIYTEJJZKVFNR-UHFFFAOYSA-N 0.000 claims 1
- MLENIDSWDIOPDU-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[4-(2-oxoimidazolidin-1-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=CC(=CC=2)N2C(NCC2)=O)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 MLENIDSWDIOPDU-UHFFFAOYSA-N 0.000 claims 1
- MCFXHZHKKLHALL-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[4-(propan-2-ylsulfamoyl)phenyl]pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)NC(C)C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 MCFXHZHKKLHALL-UHFFFAOYSA-N 0.000 claims 1
- MKBOTAVPIZHXSY-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[4-(trifluoromethyl)-4,5,6,7-tetrahydroimidazo[4,5-c]pyridin-1-yl]pyridine-2-carboxamide Chemical compound FC(F)(F)C1NCCC2=C1N=CN2C(C=1)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 MKBOTAVPIZHXSY-UHFFFAOYSA-N 0.000 claims 1
- IQCMDAGESBTEGG-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[4-(trifluoromethyl)imidazol-1-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(F)(F)F)=CN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 IQCMDAGESBTEGG-UHFFFAOYSA-N 0.000 claims 1
- PDPRUTBJSBYJMK-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[5-(trifluoromethyl)pyridin-3-yl]pyridine-2-carboxamide Chemical compound FC(F)(F)C1=CN=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 PDPRUTBJSBYJMK-UHFFFAOYSA-N 0.000 claims 1
- PKKTWVWHPTYOAW-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(1-methyl-2-oxopyrrolidin-3-yl)pyridin-3-yl]pyridine-2-carboxamide Chemical compound O=C1N(C)CCC1C1=CC=C(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)C=N1 PKKTWVWHPTYOAW-UHFFFAOYSA-N 0.000 claims 1
- CDSVDQUEAQEVNU-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(OCC(F)(F)F)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 CDSVDQUEAQEVNU-UHFFFAOYSA-N 0.000 claims 1
- WLBOLZRNHWXDAF-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(2,2,2-trifluoroethyl)-7,8-dihydro-5h-1,6-naphthyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=C2CN(CC(F)(F)F)CCC2=NC=C1C(C=1)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 WLBOLZRNHWXDAF-UHFFFAOYSA-N 0.000 claims 1
- HHYPKBOJJRBKOA-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(2,2-dimethylpropyl)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(CC(C)(C)C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 HHYPKBOJJRBKOA-UHFFFAOYSA-N 0.000 claims 1
- DVJLXJHDFJUWIS-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(2-methoxyethylamino)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(NCCOC)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 DVJLXJHDFJUWIS-UHFFFAOYSA-N 0.000 claims 1
- QJBICXBKPIAIDN-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(2-methylpropylsulfanyl)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(SCC(C)C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 QJBICXBKPIAIDN-UHFFFAOYSA-N 0.000 claims 1
- KQWPJCHHUHXQIW-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(dimethylamino)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(N(C)C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 KQWPJCHHUHXQIW-UHFFFAOYSA-N 0.000 claims 1
- WIJIZIFAAWYWSS-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(ethylamino)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(NCC)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 WIJIZIFAAWYWSS-UHFFFAOYSA-N 0.000 claims 1
- CCAJGWCPXSPDAF-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(trifluoromethyl)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(F)(F)F)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 CCAJGWCPXSPDAF-UHFFFAOYSA-N 0.000 claims 1
- PSIMXSRMFLQFGJ-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-furo[3,2-b]pyridin-6-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=C3OC=CC3=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 PSIMXSRMFLQFGJ-UHFFFAOYSA-N 0.000 claims 1
- GQHFMRSHSWGKLA-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-imidazo[1,2-a]pyridin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2N3C=CC=CC3=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 GQHFMRSHSWGKLA-UHFFFAOYSA-N 0.000 claims 1
- WFGZWQJMZCICOK-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-imidazo[4,5-b]pyridin-1-ylpyridine-2-carboxamide Chemical compound C=1C(N2C3=CC=CN=C3N=C2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 WFGZWQJMZCICOK-UHFFFAOYSA-N 0.000 claims 1
- BSAGZPRHCTWICK-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-imidazo[4,5-b]pyridin-3-ylpyridine-2-carboxamide Chemical compound C=1C(N2C3=NC=CC=C3N=C2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 BSAGZPRHCTWICK-UHFFFAOYSA-N 0.000 claims 1
- AWTXUPWCHCJCQT-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-imidazo[4,5-c]pyridin-1-ylpyridine-2-carboxamide Chemical compound C=1C(N2C3=CC=NC=C3N=C2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 AWTXUPWCHCJCQT-UHFFFAOYSA-N 0.000 claims 1
- SSBHVJGIWMTWBB-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-imidazol-1-ylpyridine-2-carboxamide Chemical compound C=1C(N2C=NC=C2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 SSBHVJGIWMTWBB-UHFFFAOYSA-N 0.000 claims 1
- CLPUKMIIBZWEIT-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-isoquinolin-4-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C3=CC=CC=C3C=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 CLPUKMIIBZWEIT-UHFFFAOYSA-N 0.000 claims 1
- FDENWWSRCRMZTK-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-phenylpyridine-2-carboxamide Chemical compound C=1C(C=2C=CC=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 FDENWWSRCRMZTK-UHFFFAOYSA-N 0.000 claims 1
- QSLDECRRWPIQFB-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-pyrazin-2-ylpyridine-2-carboxamide Chemical compound C=1C(C=2N=CC=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 QSLDECRRWPIQFB-UHFFFAOYSA-N 0.000 claims 1
- WZOKIKOXWFAJPO-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-pyridin-3-yl-6-(trifluoromethyl)pyridine-2-carboxamide Chemical compound N=1C(C(F)(F)F)=CC(C=2C=NC=CC=2)=CC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 WZOKIKOXWFAJPO-UHFFFAOYSA-N 0.000 claims 1
- SZZKJPNBENKCOL-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=NC=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 SZZKJPNBENKCOL-UHFFFAOYSA-N 0.000 claims 1
- CEUXPAJIHAMDHP-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-pyridin-3-ylquinoline-2-carboxamide Chemical compound C=1C(C=2C=NC=CC=2)=C2C=CC=CC2=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 CEUXPAJIHAMDHP-UHFFFAOYSA-N 0.000 claims 1
- DCOLXDBAPJCAFC-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-quinolin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=C3C=CC=CC3=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 DCOLXDBAPJCAFC-UHFFFAOYSA-N 0.000 claims 1
- WYJWCEANLTYWTF-UHFFFAOYSA-N n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-2-phenylpyridine-4-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2C=C(N=CC=2)C=2C=CC=CC=2)=C1 WYJWCEANLTYWTF-UHFFFAOYSA-N 0.000 claims 1
- WOMAYAFDTFYGQZ-UHFFFAOYSA-N n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-4-(3-oxopiperazin-1-yl)pyridine-2-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)N2CC(=O)NCC2)=C1 WOMAYAFDTFYGQZ-UHFFFAOYSA-N 0.000 claims 1
- PKYSWTANUVYWLS-UHFFFAOYSA-N n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-4-morpholin-4-ylpyridine-2-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)N2CCOCC2)=C1 PKYSWTANUVYWLS-UHFFFAOYSA-N 0.000 claims 1
- PFSJJBKGIXSPHS-UHFFFAOYSA-N n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-4-phenylpyridine-2-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=CC=CC=2)=C1 PFSJJBKGIXSPHS-UHFFFAOYSA-N 0.000 claims 1
- JYQLUKILLCAADR-UHFFFAOYSA-N n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC=CC=2)=C1 JYQLUKILLCAADR-UHFFFAOYSA-N 0.000 claims 1
- IAFYRYKGLRMXEU-UHFFFAOYSA-N n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-5-phenylpyridine-3-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2C=C(C=NC=2)C=2C=CC=CC=2)=C1 IAFYRYKGLRMXEU-UHFFFAOYSA-N 0.000 claims 1
- ZSROJHFZIVYSMI-UHFFFAOYSA-N n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-5-pyridin-3-ylpyridine-3-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2C=C(C=NC=2)C=2C=NC=CC=2)=C1 ZSROJHFZIVYSMI-UHFFFAOYSA-N 0.000 claims 1
- MKJSHVZGTNLRAM-UHFFFAOYSA-N n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-6-phenylpyridine-2-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=C(C=CC=2)C=2C=CC=CC=2)=C1 MKJSHVZGTNLRAM-UHFFFAOYSA-N 0.000 claims 1
- XZHNORWGXWLOLL-UHFFFAOYSA-N n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-6-pyridin-3-ylpyridine-2-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=C(C=CC=2)C=2C=NC=CC=2)=C1 XZHNORWGXWLOLL-UHFFFAOYSA-N 0.000 claims 1
- YOZDNZWJLCHYAF-UHFFFAOYSA-N n-[3-(4-propan-2-yl-1,2,4-triazol-3-yl)phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound CC(C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC=CC=2)=C1 YOZDNZWJLCHYAF-UHFFFAOYSA-N 0.000 claims 1
- ZWGFJPOMULUDJA-UHFFFAOYSA-N n-[3-[4-(2-acetamidoethyl)-1,2,4-triazol-3-yl]phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound CC(=O)NCCN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC=CC=2)=C1 ZWGFJPOMULUDJA-UHFFFAOYSA-N 0.000 claims 1
- QJDGQFRJJWEABP-UHFFFAOYSA-N n-[3-[4-(3-amino-3-oxopropyl)-1,2,4-triazol-3-yl]phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound NC(=O)CCN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC=CC=2)=C1 QJDGQFRJJWEABP-UHFFFAOYSA-N 0.000 claims 1
- MMLSXESZMOJTSL-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethyl)-1,2,4-triazol-3-yl]phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=NC=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1CC1CC1 MMLSXESZMOJTSL-UHFFFAOYSA-N 0.000 claims 1
- CJMHCJTZSYOBPU-UHFFFAOYSA-N n-[3-[4-(oxan-4-yl)-1,2,4-triazol-3-yl]phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=NC=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CCOCC1 CJMHCJTZSYOBPU-UHFFFAOYSA-N 0.000 claims 1
- CSCUXDGJDWIJCL-UHFFFAOYSA-N n-[3-[4-[(1-hydroxycyclopropyl)methyl]-1,2,4-triazol-3-yl]phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C1=NN=C(C=2C=C(NC(=O)C=3N=CC=C(C=3)C=3C=NC=CC=3)C=CC=2)N1CC1(O)CC1 CSCUXDGJDWIJCL-UHFFFAOYSA-N 0.000 claims 1
- BVOBNMVXPBIOMV-KRWDZBQOSA-N n-[3-[4-[(1s)-1-cyclopropylethyl]-1,2,4-triazol-3-yl]phenyl]-4-(6-cyclopropylpyridin-3-yl)pyridine-2-carboxamide Chemical compound C1([C@H](C)N2C(=NN=C2)C=2C=C(NC(=O)C=3N=CC=C(C=3)C=3C=NC(=CC=3)C3CC3)C=CC=2)CC1 BVOBNMVXPBIOMV-KRWDZBQOSA-N 0.000 claims 1
- QSBUJZCNLVMSKA-OAHLLOKOSA-N n-[3-[4-[(2r)-1-hydroxypropan-2-yl]-1,2,4-triazol-3-yl]phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound OC[C@@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC=CC=2)=C1 QSBUJZCNLVMSKA-OAHLLOKOSA-N 0.000 claims 1
- LBFWQZDYRKJISZ-OAHLLOKOSA-N n-[3-[4-[(2r)-2-hydroxypropyl]-1,2,4-triazol-3-yl]phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C[C@@H](O)CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC=CC=2)=C1 LBFWQZDYRKJISZ-OAHLLOKOSA-N 0.000 claims 1
- QSBUJZCNLVMSKA-HNNXBMFYSA-N n-[3-[4-[(2s)-1-hydroxypropan-2-yl]-1,2,4-triazol-3-yl]phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound OC[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC=CC=2)=C1 QSBUJZCNLVMSKA-HNNXBMFYSA-N 0.000 claims 1
- LBFWQZDYRKJISZ-HNNXBMFYSA-N n-[3-[4-[(2s)-2-hydroxypropyl]-1,2,4-triazol-3-yl]phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C[C@H](O)CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC=CC=2)=C1 LBFWQZDYRKJISZ-HNNXBMFYSA-N 0.000 claims 1
- ZYYCJXOQDWDLGN-KRWDZBQOSA-N n-[3-[4-[(2s)-butan-2-yl]-1,2,4-triazol-3-yl]phenyl]-4-(6-cyclopropylpyridin-3-yl)pyridine-2-carboxamide Chemical compound CC[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 ZYYCJXOQDWDLGN-KRWDZBQOSA-N 0.000 claims 1
- JOAGLBRFMWKWAY-UHFFFAOYSA-N n-[6-(3-cyclopropylimidazol-4-yl)pyridin-2-yl]-4-(6-cyclopropylpyridin-3-yl)pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(N=1)=CC=CC=1C1=CN=CN1C1CC1 JOAGLBRFMWKWAY-UHFFFAOYSA-N 0.000 claims 1
- BZSPITOKXNYMIL-UHFFFAOYSA-N n-[6-(3-cyclopropylimidazol-4-yl)pyridin-2-yl]-4-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(C)(O)C)=CC=C1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NC=2)C2CC2)=C1 BZSPITOKXNYMIL-UHFFFAOYSA-N 0.000 claims 1
- QSBJEMJHIREIDF-UHFFFAOYSA-N n-[6-(3-cyclopropylimidazol-4-yl)pyridin-2-yl]-4-quinolin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=C3C=CC=CC3=NC=2)=CC=NC=1C(=O)NC(N=1)=CC=CC=1C1=CN=CN1C1CC1 QSBJEMJHIREIDF-UHFFFAOYSA-N 0.000 claims 1
- LTLQDJLAQRIRKR-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-3-(1,5-naphthyridin-3-yl)benzamide Chemical compound C=1C=CC(C=2C=C3N=CC=CC3=NC=2)=CC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 LTLQDJLAQRIRKR-UHFFFAOYSA-N 0.000 claims 1
- FCPPUDFGPFUSRX-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-3-(4,5,6,7-tetrahydrobenzimidazol-1-yl)benzamide Chemical compound C=1C=CC(N2C=3CCCCC=3N=C2)=CC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 FCPPUDFGPFUSRX-UHFFFAOYSA-N 0.000 claims 1
- CUPFKQJBPJLHMP-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-3-(4,5-dimethylimidazol-1-yl)benzamide Chemical compound CC1=C(C)N=CN1C1=CC=CC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 CUPFKQJBPJLHMP-UHFFFAOYSA-N 0.000 claims 1
- MMQIDSMZFJLWGS-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-3-(4-propan-2-ylimidazol-1-yl)benzamide Chemical compound C1=NC(C(C)C)=CN1C1=CC=CC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 MMQIDSMZFJLWGS-UHFFFAOYSA-N 0.000 claims 1
- UOCPJOQEMBOMOO-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-3-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]benzamide Chemical compound C1=NC(C(C)(O)C)=CC=C1C1=CC=CC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 UOCPJOQEMBOMOO-UHFFFAOYSA-N 0.000 claims 1
- BHKDDULOOMQUMP-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-3-pyridin-3-ylbenzamide Chemical compound C=1C=CC(C=2C=NC=CC=2)=CC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 BHKDDULOOMQUMP-UHFFFAOYSA-N 0.000 claims 1
- PHLIEZXYUULPHF-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-(3-hydroxypiperidin-1-yl)pyridine-2-carboxamide Chemical compound C1C(O)CCCN1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 PHLIEZXYUULPHF-UHFFFAOYSA-N 0.000 claims 1
- YZPHWCAWCRTXRI-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-(4,5,6,7-tetrahydrobenzimidazol-1-yl)pyridine-2-carboxamide Chemical compound C=1C(N2C=3CCCCC=3N=C2)=CC=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 YZPHWCAWCRTXRI-UHFFFAOYSA-N 0.000 claims 1
- KJARSCYCCLZWRM-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-(4-ethyl-3-oxopiperazin-1-yl)pyridine-2-carboxamide Chemical compound C1C(=O)N(CC)CCN1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 KJARSCYCCLZWRM-UHFFFAOYSA-N 0.000 claims 1
- VQPJSWDNPZOEKX-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-(4-methylimidazol-1-yl)pyridine-2-carboxamide Chemical compound C1=NC(C)=CN1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 VQPJSWDNPZOEKX-UHFFFAOYSA-N 0.000 claims 1
- UJMZVBGKKLCZBV-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-(4-methylsulfonylphenyl)pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 UJMZVBGKKLCZBV-UHFFFAOYSA-N 0.000 claims 1
- LNYQTEWKYOBOOO-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-(4-phenylimidazol-1-yl)pyridine-2-carboxamide Chemical compound C=1C(N2C=C(N=C2)C=2C=CC=CC=2)=CC=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 LNYQTEWKYOBOOO-UHFFFAOYSA-N 0.000 claims 1
- GFRXYBKWDFPKGO-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-(4-propan-2-ylimidazol-1-yl)pyridine-2-carboxamide Chemical compound C1=NC(C(C)C)=CN1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 GFRXYBKWDFPKGO-UHFFFAOYSA-N 0.000 claims 1
- RGPKITGJSDQXKA-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-[4-(1,1,2,2,2-pentafluoroethyl)imidazol-1-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(F)(F)C(F)(F)F)=CN1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 RGPKITGJSDQXKA-UHFFFAOYSA-N 0.000 claims 1
- JZFLHCHLJVHJON-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-[4-(methylsulfamoyl)phenyl]pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)NC)=CC=C1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 JZFLHCHLJVHJON-UHFFFAOYSA-N 0.000 claims 1
- FFOVSBHCQMETLA-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-[4-(trifluoromethyl)-4,5,6,7-tetrahydroimidazo[4,5-c]pyridin-1-yl]pyridine-2-carboxamide Chemical compound FC(F)(F)C1NCCC2=C1N=CN2C(C=1)=CC=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 FFOVSBHCQMETLA-UHFFFAOYSA-N 0.000 claims 1
- HLVLRZLEIYSGOP-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-[4-(trifluoromethyl)imidazol-1-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(F)(F)F)=CN1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 HLVLRZLEIYSGOP-UHFFFAOYSA-N 0.000 claims 1
- SLEFVAGTBGMNSN-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-[5-methyl-4-(trifluoromethyl)-6,7-dihydro-4h-imidazo[4,5-c]pyridin-1-yl]pyridine-2-carboxamide Chemical compound FC(F)(F)C1N(C)CCC2=C1N=CN2C(C=1)=CC=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 SLEFVAGTBGMNSN-UHFFFAOYSA-N 0.000 claims 1
- RRFGRBKXRSMWFQ-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=NC=CC=2)=CC=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 RRFGRBKXRSMWFQ-UHFFFAOYSA-N 0.000 claims 1
- ZCUZEIWNPXRKAG-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-quinolin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=C3C=CC=CC3=NC=2)=CC=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 ZCUZEIWNPXRKAG-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22507609P | 2009-07-13 | 2009-07-13 | |
| US22507909P | 2009-07-13 | 2009-07-13 | |
| US61/225,076 | 2009-07-13 | ||
| US61/225,079 | 2009-07-13 | ||
| US28926309P | 2009-12-22 | 2009-12-22 | |
| US61/289,263 | 2009-12-22 | ||
| PCT/US2010/041739 WO2011008709A1 (en) | 2009-07-13 | 2010-07-12 | Apoptosis signal-regulating kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015040924A Division JP2015098500A (ja) | 2009-07-13 | 2015-03-03 | アポトーシスシグナル調節キナーゼ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012532931A JP2012532931A (ja) | 2012-12-20 |
| JP2012532931A5 true JP2012532931A5 (enExample) | 2014-10-09 |
| JP5745721B2 JP5745721B2 (ja) | 2015-07-08 |
Family
ID=42670422
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520706A Active JP5745721B2 (ja) | 2009-07-13 | 2010-07-12 | アポトーシスシグナル調節キナーゼ阻害剤 |
| JP2015040924A Withdrawn JP2015098500A (ja) | 2009-07-13 | 2015-03-03 | アポトーシスシグナル調節キナーゼ阻害剤 |
| JP2017007269A Withdrawn JP2017071647A (ja) | 2009-07-13 | 2017-01-19 | アポトーシスシグナル調節キナーゼ阻害剤 |
| JP2018144888A Pending JP2018184464A (ja) | 2009-07-13 | 2018-08-01 | アポトーシスシグナル調節キナーゼ阻害剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015040924A Withdrawn JP2015098500A (ja) | 2009-07-13 | 2015-03-03 | アポトーシスシグナル調節キナーゼ阻害剤 |
| JP2017007269A Withdrawn JP2017071647A (ja) | 2009-07-13 | 2017-01-19 | アポトーシスシグナル調節キナーゼ阻害剤 |
| JP2018144888A Pending JP2018184464A (ja) | 2009-07-13 | 2018-08-01 | アポトーシスシグナル調節キナーゼ阻害剤 |
Country Status (27)
| Country | Link |
|---|---|
| US (7) | US8378108B2 (enExample) |
| EP (4) | EP2454250B1 (enExample) |
| JP (4) | JP5745721B2 (enExample) |
| KR (3) | KR20170081722A (enExample) |
| CN (1) | CN102482257B (enExample) |
| AR (1) | AR077564A1 (enExample) |
| AU (1) | AU2010273597B2 (enExample) |
| BR (1) | BR112012000894A2 (enExample) |
| CA (1) | CA2767894C (enExample) |
| CY (1) | CY1119889T1 (enExample) |
| DK (2) | DK2454250T3 (enExample) |
| ES (3) | ES2662397T3 (enExample) |
| HR (2) | HRP20150185T1 (enExample) |
| HU (1) | HUE038529T2 (enExample) |
| LT (1) | LT2933252T (enExample) |
| ME (1) | ME02104B (enExample) |
| MX (1) | MX2012000708A (enExample) |
| NO (1) | NO2933252T3 (enExample) |
| NZ (1) | NZ597533A (enExample) |
| PL (3) | PL2933252T3 (enExample) |
| PT (3) | PT2454250E (enExample) |
| RS (2) | RS56981B1 (enExample) |
| SI (3) | SI3363797T1 (enExample) |
| SM (2) | SMT201800172T1 (enExample) |
| TW (3) | TWI598347B (enExample) |
| UY (1) | UY32786A (enExample) |
| WO (1) | WO2011008709A1 (enExample) |
Families Citing this family (208)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009279787B2 (en) | 2008-08-04 | 2014-05-29 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| TWI598347B (zh) | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| EP2528441A4 (en) | 2010-01-25 | 2013-07-10 | Chdi Foundation Inc | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF |
| MX2012015105A (es) * | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Inhibidores de cinasa de regulacion mediante señal de apoptosis. |
| EP2598661B1 (en) | 2010-07-26 | 2017-09-27 | Biomatrica, INC. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
| WO2012018638A2 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
| JP5927201B2 (ja) | 2010-12-16 | 2016-06-01 | カルチャン リミテッド | Ａｓｋ１阻害ピロロピリミジン誘導体 |
| US9981918B2 (en) * | 2011-08-30 | 2018-05-29 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| JP2014525443A (ja) | 2011-08-30 | 2014-09-29 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | キヌレニン−３−モノオキシゲナーゼインヒビター、医薬組成物、およびこれらの使用方法 |
| UY34573A (es) * | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| AU2015201188B2 (en) * | 2012-01-27 | 2016-12-15 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitor |
| EP2934572A4 (en) | 2012-12-20 | 2016-11-23 | Biomatrica Inc | FORMULATIONS AND METHODS FOR STABILIZING PCR REAGENTS |
| UY35212A (es) * | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
| EP3007689B1 (en) | 2013-01-10 | 2018-03-07 | Pulmokine, Inc. | Non-selective kinase inhibitors |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| EP3007556B1 (en) | 2013-06-13 | 2020-05-20 | Biomatrica, INC. | Cell stabilization |
| US9249151B2 (en) * | 2013-08-23 | 2016-02-02 | Boehringer Ingelheim International Gmbh | Bis-amido pyridines |
| EP3054937B1 (en) | 2013-10-11 | 2023-07-26 | Pulmokine, Inc. | Spray dry formulations |
| WO2015070366A1 (en) * | 2013-11-12 | 2015-05-21 | Merck Sharp & Dohme Corp. | Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
| US20150148345A1 (en) | 2013-11-26 | 2015-05-28 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| GB201321748D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| CA2937320A1 (en) | 2014-01-20 | 2015-07-23 | Gilead Sciences, Inc. | Therapies for treating cancers |
| WO2015187499A1 (en) | 2014-06-03 | 2015-12-10 | Gilead Sciences, Inc. | Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor |
| JP6661554B2 (ja) | 2014-06-10 | 2020-03-11 | バイオマトリカ，インク． | 周囲温度における血小板の安定化 |
| KR20170026633A (ko) | 2014-07-17 | 2017-03-08 | 씨에이치디아이 파운데이션, 인코포레이티드 | Hiv-관련 장애의 치료 방법 및 치료용 조성물 |
| TW201618781A (zh) | 2014-08-13 | 2016-06-01 | 吉李德科學股份有限公司 | 治療肺高血壓之方法 |
| MX2017003933A (es) | 2014-09-24 | 2017-06-30 | Gilead Sciences Inc | Metodos de tratamiento de la enfermedad hepatica. |
| EP4276095A3 (en) * | 2014-12-23 | 2024-01-17 | Gilead Sciences, Inc. | Processes for preparing ask1 inhibitors |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| PL3097102T3 (pl) | 2015-03-04 | 2018-04-30 | Gilead Sciences Inc | Związki 4,6-diamino-pirydo[3,2-d]pirymidyny modulujące działanie receptora toll-podobnego |
| RS58639B1 (sr) | 2015-07-06 | 2019-05-31 | Gilead Sciences Inc | Cot modulatori i postupci za njihovu upotrebu |
| LT3319963T (lt) * | 2015-07-09 | 2020-03-25 | Janssen Pharmaceutica Nv | Pakeistieji 4-azaindolai ir jų, kaip glun2b receptoriaus moduliatorių, panaudojimas |
| KR200483190Y1 (ko) | 2015-09-11 | 2017-04-13 | 주식회사 엔젤악기 | 바로크식 운지법과 독일식 운지법의 선택 적용이 가능한 리코더 링 |
| TW201725044A (zh) | 2015-10-01 | 2017-07-16 | 基利科學股份有限公司 | 用於治療癌症之btk抑制劑及查核點抑制劑之組合 |
| US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| AU2016358100B2 (en) | 2015-11-19 | 2021-05-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| JP6827048B2 (ja) | 2015-12-08 | 2021-02-10 | バイオマトリカ，インク． | 赤血球沈降速度の低下 |
| CU20180059A7 (es) | 2015-12-17 | 2018-10-04 | Gilead Sciences Inc | Compuestos inhibidores de la quinasa de unión a tank |
| TW201726623A (zh) | 2015-12-17 | 2017-08-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| TWI850624B (zh) | 2015-12-22 | 2024-08-01 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| CA3016081A1 (en) | 2016-03-04 | 2017-09-08 | Gilead Sciences, Inc. | Compositions and combinations of autotaxin inhibitors |
| BR112018068681A2 (pt) | 2016-03-16 | 2019-01-15 | Bayer Cropscience Ag | derivados de n-(cianobenzil)-6-(ciclopropil-carbonilamino)-4-(fenil)-piridina-2-carboxamida e compostos relacionados como pesticidas e agentes de proteção de plantas |
| CA3019003A1 (en) | 2016-04-08 | 2017-10-12 | Gilead Sciences, Inc. | Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases |
| TW201808950A (zh) | 2016-05-06 | 2018-03-16 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| JP6730466B2 (ja) | 2016-06-13 | 2020-07-29 | アイ−エムエービー バイオファーマ ユーエス リミテッド | 抗ｐｄ−ｌ１抗体およびその使用 |
| DK3472167T3 (da) | 2016-06-20 | 2022-09-05 | Incyte Corp | Heterocykliske forbindelser som immunomodulatorer |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3493797A1 (en) | 2016-08-04 | 2019-06-12 | Gilead Sciences, Inc. | Cobicistat for use in cancer treatments |
| EP3504198B1 (en) | 2016-08-29 | 2023-01-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| KR102268448B1 (ko) | 2016-09-02 | 2021-06-22 | 길리애드 사이언시즈, 인코포레이티드 | 톨 유사 수용체 조정제 화합물 |
| ES2826748T3 (es) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll |
| KR20230093341A (ko) | 2016-10-27 | 2023-06-27 | 풀모킨 인코포레이티드 | 폐고혈압을 치료하기 위한 병용 요법 |
| WO2018085069A1 (en) | 2016-11-03 | 2018-05-11 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
| EP3538097A1 (en) * | 2016-11-11 | 2019-09-18 | Gilead Sciences, Inc. | Methods of treating liver disease |
| CN110036005B (zh) * | 2016-11-16 | 2022-09-27 | 广东东阳光药业有限公司 | 酰胺衍生物及其在药物中的应用 |
| US20180141939A1 (en) | 2016-11-22 | 2018-05-24 | Gilead Sciences, Inc. | Solid forms of a bet inhibitor |
| WO2018098367A1 (en) * | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof |
| EP3558973B1 (en) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| IL295660A (en) | 2016-12-22 | 2022-10-01 | Incyte Corp | Benzooxazole derivatives as immunomodulators |
| ES2929193T3 (es) | 2016-12-22 | 2022-11-25 | Incyte Corp | Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de la internalización de PD-L1 |
| EP3558963B1 (en) | 2016-12-22 | 2022-03-23 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| WO2018133865A1 (zh) * | 2017-01-22 | 2018-07-26 | 福建广生堂药业股份有限公司 | Ask1抑制剂及其制备方法和应用 |
| CN109071538B (zh) | 2017-01-22 | 2020-03-17 | 福建广生堂药业股份有限公司 | 作为ask1抑制剂的吡啶衍生物及其制备方法和应用 |
| PL3383916T3 (pl) | 2017-01-24 | 2023-06-12 | I-Mab Biopharma Us Limited | Przeciwciała anty-cd73 i ich zastosowania |
| US11168095B2 (en) | 2017-02-07 | 2021-11-09 | Biogen Ma Inc. | ASK1 inhibiting agents |
| JP2020508326A (ja) | 2017-02-24 | 2020-03-19 | ギリアド サイエンシズ， インコーポレイテッド | ブルトン型チロシンキナーゼの阻害剤 |
| AR110998A1 (es) | 2017-02-24 | 2019-05-22 | Gilead Sciences Inc | Inhibidores de la tirosina cinasa de bruton |
| WO2018157277A1 (en) * | 2017-02-28 | 2018-09-07 | Eli Lilly And Company | Isoquinolin and naphthydrin compounds |
| EP3590931A4 (en) * | 2017-03-03 | 2020-11-18 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | AMIDE DERIVATIVE INHIBITOR, PROCESS OF PREPARATION AND APPLICATION |
| JOP20180017A1 (ar) | 2017-03-14 | 2019-01-30 | Gilead Sciences Inc | مثبط كيناز منظم لإشارة تلاشي خلايا |
| EP3601250A4 (en) * | 2017-03-27 | 2020-11-25 | Pharmakea, Inc. | APOPTOSIS SIGNAL REGULATION KINASE 1 (ASK 1) INHIBITOR COMPOUNDS |
| CN110475556A (zh) | 2017-03-28 | 2019-11-19 | 吉利德科学公司 | 治疗肝疾病的方法 |
| JOP20190221A1 (ar) * | 2017-04-05 | 2019-09-23 | Seal Rock Therapeutics Inc | مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها |
| AU2018250614A1 (en) | 2017-04-12 | 2019-10-17 | Gilead Sciences, Inc. | Methods of treating liver disease |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| JP7377718B2 (ja) * | 2017-05-12 | 2023-11-10 | エナンタ ファーマシューティカルズ インコーポレイテッド | アポトーシスシグナル調節キナーゼ１阻害剤およびその使用方法 |
| WO2018218042A1 (en) * | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2018218044A2 (en) * | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals Inc | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10450301B2 (en) | 2017-05-25 | 2019-10-22 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CN110770233B (zh) * | 2017-06-19 | 2022-07-26 | 广东东阳光药业有限公司 | 稠合双环类化合物及其在药物中的应用 |
| GB201711234D0 (en) * | 2017-07-12 | 2017-08-23 | Galapagos Nv | Pyrrolopyrimidine and pyrrolopyridine derivatives |
| TW201908306A (zh) * | 2017-07-18 | 2019-03-01 | 大陸商南京聖和藥業股份有限公司 | 作為ask抑制劑的雜環化合物及其應用 |
| EP3284739A1 (de) | 2017-07-19 | 2018-02-21 | Bayer CropScience Aktiengesellschaft | Substituierte (het)arylverbindungen als schädlingsbekämpfungsmittel |
| WO2019034096A1 (en) * | 2017-08-17 | 2019-02-21 | Sunshine Lake Pharma Co., Ltd. | FUSED BICYCLIC COMPOUNDS AND THEIR USES IN MEDICINE |
| US10597382B2 (en) | 2017-08-28 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CN109456308B (zh) * | 2017-09-06 | 2022-11-29 | 南京圣和药业股份有限公司 | 作为ask抑制剂的杂环化合物及其应用 |
| CN111315380A (zh) * | 2017-09-08 | 2020-06-19 | 弗朗塞拉美国制药有限责任公司 | 凋亡信号调节激酶抑制剂及其用途 |
| CN109232538B (zh) * | 2017-10-12 | 2020-07-24 | 深圳市塔吉瑞生物医药有限公司 | 一种1,2,4-三氮唑类化合物 |
| CN107793400B (zh) * | 2017-10-31 | 2020-01-31 | 武汉九州钰民医药科技有限公司 | 吡啶类化合物及其在制备治疗肝脏疾病的药物中的应用 |
| WO2019099307A1 (en) * | 2017-11-17 | 2019-05-23 | Hepagene Therapeutics, Inc. | Urea derivatives as inhibitors of ask1 |
| CN109956928B (zh) * | 2017-12-14 | 2021-07-09 | 四川科伦博泰生物医药股份有限公司 | 吡啶类化合物、其制备方法及用途 |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| US11434249B1 (en) | 2018-01-02 | 2022-09-06 | Seal Rock Therapeutics, Inc. | ASK1 inhibitor compounds and uses thereof |
| CN111655678B (zh) * | 2018-01-05 | 2023-08-22 | 广州市恒诺康医药科技有限公司 | 细胞凋亡信号调节激酶-1抑制剂及其应用 |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN110294746B (zh) * | 2018-03-21 | 2023-01-31 | 山东轩竹医药科技有限公司 | 一种新的ask1抑制剂及其应用 |
| CN110294742B (zh) * | 2018-03-21 | 2023-01-31 | 山东轩竹医药科技有限公司 | 并环类ask1抑制剂及其应用 |
| RS64055B1 (sr) | 2018-03-30 | 2023-04-28 | Incyte Corp | Heterociklična jedinjenja kao imunomodulatori |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US10919911B2 (en) | 2018-04-12 | 2021-02-16 | Terns, Inc. | Tricyclic ASK1 inhibitors |
| WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
| KR102798464B1 (ko) * | 2018-05-02 | 2025-04-21 | 이난타 파마슈티칼스, 인코포레이티드 | 아폽토시스 신호 조절 키나제 1 억제제를 포함하는 테트라졸 및 이의 사용 방법 |
| WO2019213239A1 (en) | 2018-05-02 | 2019-11-07 | Enanta Pharmaceuticals Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| JP2021523151A (ja) | 2018-05-11 | 2021-09-02 | ホスホレックス、インコーポレイテッド | 負の表面電荷を有するマイクロ粒子及びナノ粒子 |
| EP4219492B1 (en) | 2018-05-11 | 2024-11-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US10703733B2 (en) | 2018-05-14 | 2020-07-07 | Gilead Sciences, Inc. | MCL-1 inhibitors |
| JP2021528456A (ja) | 2018-06-27 | 2021-10-21 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Ａｓｋ１阻害剤 |
| US10654833B2 (en) | 2018-06-28 | 2020-05-19 | Hepatikos Therapeutics, Llc | ASK1 isoindolin-1-one inhibitors and methods of use thereof |
| BR112020026746A2 (pt) | 2018-07-13 | 2021-03-30 | Gilead Sciences, Inc. | Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição. |
| CN112638912B (zh) * | 2018-07-20 | 2022-04-26 | 福建广生中霖生物科技有限公司 | 作为ask1抑制剂的晶型及其制备方法和应用 |
| CN110818683B (zh) * | 2018-08-10 | 2023-04-14 | 中国科学院上海药物研究所 | 2-吡啶取代脲结构小分子化合物及其合成和应用 |
| WO2020030107A1 (zh) * | 2018-08-10 | 2020-02-13 | 江苏豪森药业集团有限公司 | 一种含有酰胺类衍生物的药物组合物及其制备方法和应用 |
| TW202021967A (zh) * | 2018-08-14 | 2020-06-16 | 大陸商江蘇豪森藥業集團有限公司 | 凋亡信號調節激酶１抑制劑的鹽及其晶型 |
| CN113227070A (zh) * | 2018-08-14 | 2021-08-06 | 比奥根Ma公司 | Ask1抑制剂 |
| ES2945183T3 (es) * | 2018-08-14 | 2023-06-29 | Biogen Ma Inc | Compuestos macrocíclicos de piridina como agentes inhibidores de ASK1 |
| US10968199B2 (en) | 2018-08-22 | 2021-04-06 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US20210213006A1 (en) * | 2018-08-29 | 2021-07-15 | Seal Rock Therapeutics, Inc. | Methods of treating neurodegenerative diseases |
| CN112384508B (zh) * | 2018-09-30 | 2022-08-02 | 山东轩竹医药科技有限公司 | 三并环类ask1抑制剂及其应用 |
| US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
| CN112955435B (zh) | 2018-10-24 | 2024-09-06 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| FI3873903T3 (fi) | 2018-10-31 | 2024-03-26 | Gilead Sciences Inc | Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| US11345699B2 (en) | 2018-11-19 | 2022-05-31 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CN109608441A (zh) * | 2018-12-26 | 2019-04-12 | 都创(上海)医药科技有限公司 | 一种ask1抑制剂的合成工艺 |
| PE20211907A1 (es) | 2019-01-15 | 2021-09-28 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4) |
| KR102725082B1 (ko) | 2019-02-19 | 2024-11-04 | 길리애드 사이언시즈, 인코포레이티드 | Fxr 효능제의 고체 형태 |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| CA3129011C (en) | 2019-03-07 | 2023-12-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| CA3132044A1 (en) | 2019-03-11 | 2020-09-17 | Brian Kirby | Formulations of a compound and uses thereof |
| WO2020198214A1 (en) | 2019-03-25 | 2020-10-01 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| TWI770527B (zh) | 2019-06-14 | 2022-07-11 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
| CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| MX2021015452A (es) | 2019-06-25 | 2022-02-11 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso. |
| JP7665593B2 (ja) | 2019-08-09 | 2025-04-21 | インサイト・コーポレイション | Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩 |
| AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
| EP4037773A1 (en) | 2019-09-30 | 2022-08-10 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| MX2022004370A (es) | 2019-10-18 | 2022-05-06 | Forty Seven Inc | Terapias de combinacion para tratar sindromes mielodisplasicos y leucemia mieloide aguda. |
| WO2021087064A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| EP4058144A1 (en) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
| CN111018831B (zh) * | 2019-11-21 | 2022-05-31 | 中国药科大学 | 细胞凋亡信号调节激酶抑制剂及其应用 |
| WO2021133948A1 (en) | 2019-12-23 | 2021-07-01 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders |
| JP7711068B2 (ja) | 2019-12-24 | 2025-07-22 | カルナバイオサイエンス株式会社 | ジアシルグリセロールキナーゼ調節化合物 |
| IL295023A (en) | 2020-02-14 | 2022-09-01 | Jounce Therapeutics Inc | Antibodies and fusion proteins that bind to ccr8 and their uses |
| KR102924836B1 (ko) | 2020-03-30 | 2026-02-09 | 길리애드 사이언시즈, 인코포레이티드 | Cot 억제제 화합물, (S)-6-(((1-(바이사이클로[1.1.1]펜탄-1-일)-1H-1,2,3-트라이아졸-4-일)2-메틸-1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)메틸)))아미노8-클로로-(네오펜틸아미노)퀴놀린-3-카르보니트릴의 고체 형태 |
| WO2021202688A1 (en) | 2020-04-02 | 2021-10-07 | Gilead Sciences, Inc. | Process for preparing a cot inhibitor compound |
| CR20220547A (es) | 2020-05-01 | 2022-12-15 | Gilead Sciences Inc | Compuestos de 2,4-dioxopirimidina inhibidores de cd73 |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| KR102913125B1 (ko) | 2020-06-03 | 2026-01-20 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| CN113831323B (zh) * | 2020-06-24 | 2025-08-29 | 武汉人福创新药物研发中心有限公司 | 芳杂环酰胺类化合物及其用途 |
| CN111808079A (zh) * | 2020-08-05 | 2020-10-23 | 中国药科大学 | 吲哚类ask1小分子抑制剂及其制备方法和应用 |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
| EP4240739A1 (en) | 2020-11-06 | 2023-09-13 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
| US12091404B2 (en) | 2021-03-11 | 2024-09-17 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| EP4313967B1 (en) | 2021-03-29 | 2025-11-12 | Gilead Sciences, Inc. | Khk inhibitors |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| CA3218917A1 (en) | 2021-05-11 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2022241023A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| TW202345826A (zh) | 2021-06-04 | 2023-12-01 | 美商基利科學股份有限公司 | 治療nash之方法 |
| TW202311256A (zh) | 2021-06-18 | 2023-03-16 | 美商基利科學股份有限公司 | 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240025616A (ko) | 2021-06-23 | 2024-02-27 | 길리애드 사이언시즈, 인코포레이티드 | 다이아실글리세롤 키나제 조절 화합물 |
| JP2024539252A (ja) | 2021-10-28 | 2024-10-28 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジジン－３（２ｈ）－オン誘導体 |
| CA3235986A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Science, Inc. | Cd73 compounds |
| US20230203202A1 (en) | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| KR20240115978A (ko) | 2021-12-08 | 2024-07-26 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| EP4667056A1 (en) | 2021-12-22 | 2025-12-24 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| LT4245756T (lt) | 2022-03-17 | 2024-11-25 | Gilead Sciences, Inc. | Ikaros cinko pirštų šeimos skaidymo medžiagos ir jų panaudojimas |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| US20230374036A1 (en) | 2022-04-21 | 2023-11-23 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| IL317958A (en) | 2022-07-01 | 2025-02-01 | Gilead Sciences Inc | CD73 compounds |
| WO2024059216A2 (en) * | 2022-09-15 | 2024-03-21 | Vanderbilt University | 6,6 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same |
| WO2024059212A2 (en) * | 2022-09-15 | 2024-03-21 | Vanderbilt University | 6,6 western core compounds as mglu5 negative allosteric modulators and methods of making and using the same |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN116874468B (zh) * | 2022-12-24 | 2025-08-29 | 江西中医药大学 | 具有2-吡啶取代甲酰胺结构的小分子化合物的合成和应用 |
| EP4695260A1 (en) | 2023-04-11 | 2026-02-18 | Gilead Sciences, Inc. | Kras modulating compounds |
| KR20250175331A (ko) | 2023-04-21 | 2025-12-16 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| AU2024300557A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| CA1121825A (en) | 1978-04-11 | 1982-04-13 | Franco Bolasco | 2-(2-thenoylthio)-propionylglycine: method for its preparation and pharmaceutical formulations containing said compound |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US6159731A (en) | 1997-02-12 | 2000-12-12 | Massachusetts Institute Of Technology | Daxx, a Fas-binding protein that activates JNK and apoptosis |
| AUPP285898A0 (en) * | 1998-04-07 | 1998-04-30 | Fujisawa Pharmaceutical Co., Ltd. | Amido derivatives |
| US6881555B2 (en) | 1999-03-19 | 2005-04-19 | Aventis Pharmaceuticals Inc. | AKT nucleic acids, polypeptides, and uses thereof |
| ES2310515T3 (es) | 1999-03-19 | 2009-01-16 | Aventis Pharmaceuticals Inc. | Acidos nucleicos akt-3, polipeptidos y usos de los mismos. |
| WO2001068585A1 (en) * | 2000-03-14 | 2001-09-20 | Fujisawa Pharmaceutical Co., Ltd. | Novel amide compounds |
| WO2002038179A1 (en) * | 2000-11-10 | 2002-05-16 | Kissei Pharmaceutical Co., Ltd. | Preventives or remedies for endoplasmic reticulum stress-associated diseases |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US20070237770A1 (en) | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
| TW200400963A (en) | 2002-05-21 | 2004-01-16 | Wyeth Corp | R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease |
| TW200400818A (en) | 2002-05-21 | 2004-01-16 | Wyeth Corp | Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus |
| WO2005009470A1 (ja) | 2003-07-28 | 2005-02-03 | Osaka Industrial Promotion Organization | Ａｓｋ１阻害剤を有効成分とする心不全治療薬およびそのスクリーニング方法 |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| GB0324551D0 (en) | 2003-10-21 | 2003-11-26 | Karobio Ab | Novel compounds |
| US7078064B2 (en) | 2003-12-03 | 2006-07-18 | George Zabrecky | Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis |
| US20060079494A1 (en) | 2004-09-27 | 2006-04-13 | Santi Daniel V | Specific kinase inhibitors |
| TW200628159A (en) * | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | IL-12 modulatory compounds |
| EP1831168B1 (en) * | 2004-12-16 | 2014-07-02 | Vertex Pharmaceuticals Inc. | Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases. |
| EP1677113A1 (en) | 2004-12-29 | 2006-07-05 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Method for the identification of protein-protein interactions in disease related protein networks |
| US20070276050A1 (en) | 2006-02-27 | 2007-11-29 | Gilead Sciences, Inc. | Methods for identifying ASK1 inhibitors useful for preventing and/or treating cardiovascular diseases |
| WO2008011557A2 (en) | 2006-07-20 | 2008-01-24 | Borchardt Allen J | Heteroaryl inhibitors of rho kinase |
| EP2058309A4 (en) * | 2006-08-04 | 2010-12-22 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND |
| WO2008042867A2 (en) | 2006-09-29 | 2008-04-10 | Emiliem Inc. | Modulators of multiple kinases |
| CA2671194A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-20 regulated genes and pathways as targets for therapeutic intervention |
| WO2009011850A2 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| JP2010536917A (ja) | 2007-08-31 | 2010-12-02 | メルク セローノ ソシエテ アノニム | トリアゾロピリジン化合物と、ａｓｋ阻害剤としてのその化合物の利用法 |
| CA2708300A1 (en) | 2007-12-11 | 2009-06-18 | Schering Corporation | Gamma secretase modulators |
| EP2271646A1 (en) | 2008-03-31 | 2011-01-12 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
| WO2010008843A1 (en) * | 2008-06-24 | 2010-01-21 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
| WO2010045470A2 (en) | 2008-10-15 | 2010-04-22 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of hepatic disorders |
| US20110294693A1 (en) | 2008-11-17 | 2011-12-01 | The George Washington University | Compositions and Methods for Identifying Autism Spectrum Disorders |
| PA8854101A1 (es) | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa |
| JP2012521760A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| TWI598347B (zh) | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
| SI2531501T1 (sl) | 2010-02-03 | 2014-04-30 | Takeda Pharmaceutical Company Limited | Inhibitorji kinaze-1, ki regulirajo signal apoptoze |
| JP2013518909A (ja) | 2010-02-08 | 2013-05-23 | キナゲン，インク． | アロステリックキナーゼ阻害が関係する治療方法および組成物 |
| RU2018100142A (ru) | 2010-03-24 | 2019-02-20 | Амитек Терапетикс Солюшинс, Инк. | Гетероциклические соединения, эффективные для ингибирования киназы |
| MX2012015105A (es) | 2010-07-02 | 2013-05-28 | Gilead Sciences Inc | Inhibidores de cinasa de regulacion mediante señal de apoptosis. |
| TW201300380A (zh) | 2010-10-19 | 2013-01-01 | Comentis Inc | 抑制β－分泌酶活性之噁二唑化合物及其使用方法 |
| WO2012068464A2 (en) | 2010-11-18 | 2012-05-24 | University Of Delaware | Methods of treating and preventing thrombotic diseases using ask1 inhibitors |
| JP5927201B2 (ja) | 2010-12-16 | 2016-06-01 | カルチャン リミテッド | Ａｓｋ１阻害ピロロピリミジン誘導体 |
| JP2014507160A (ja) | 2011-02-22 | 2014-03-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． | 循環バイオマーカー |
| CA2838728A1 (en) | 2011-06-07 | 2012-12-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for cancer |
| TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| EP3628320B1 (en) | 2011-11-11 | 2022-03-16 | Gilead Apollo, LLC | Acc inhibitors and uses thereof |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| UY35212A (es) | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
| CR20160268A (es) | 2013-12-20 | 2016-08-16 | Gilead Sciences Inc | Inhibidores de la quinasa reguladora de la señal de apoptosis |
| CN103896990B (zh) | 2014-03-12 | 2017-02-08 | 石家庄诚志永华显示材料有限公司 | 有机电致发光材料及其应用 |
| WO2015187499A1 (en) | 2014-06-03 | 2015-12-10 | Gilead Sciences, Inc. | Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor |
| MX2017003933A (es) * | 2014-09-24 | 2017-06-30 | Gilead Sciences Inc | Metodos de tratamiento de la enfermedad hepatica. |
| EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| EP4276095A3 (en) | 2014-12-23 | 2024-01-17 | Gilead Sciences, Inc. | Processes for preparing ask1 inhibitors |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| CA2972919A1 (en) | 2015-01-09 | 2016-07-14 | Gilead Apollo, Llc | Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease |
| CN108699078A (zh) | 2016-03-02 | 2018-10-23 | 吉利德阿波罗公司 | 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法 |
| ES2921432T3 (es) | 2016-06-13 | 2022-08-25 | Gilead Sciences Inc | Derivados de azetidina como moduladores de FXR (NR1H4) |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| EP3538097A1 (en) | 2016-11-11 | 2019-09-18 | Gilead Sciences, Inc. | Methods of treating liver disease |
| JOP20180017A1 (ar) | 2017-03-14 | 2019-01-30 | Gilead Sciences Inc | مثبط كيناز منظم لإشارة تلاشي خلايا |
| EP4424364B1 (en) | 2017-03-28 | 2026-01-21 | Gilead Sciences, Inc. | Combinations for use in the treatment of cirrhosis and liver fibrosis |
| CN110475556A (zh) | 2017-03-28 | 2019-11-19 | 吉利德科学公司 | 治疗肝疾病的方法 |
| AU2018250614A1 (en) | 2017-04-12 | 2019-10-17 | Gilead Sciences, Inc. | Methods of treating liver disease |
| CA3077273A1 (en) | 2017-10-06 | 2019-04-11 | Gilead Sciences, Inc. | Combination therapy comprising an acc inhibitor |
-
2010
- 2010-07-06 TW TW104112851A patent/TWI598347B/zh active
- 2010-07-06 TW TW099122220A patent/TWI491606B/zh active
- 2010-07-06 TW TW106124595A patent/TWI625121B/zh active
- 2010-07-12 NO NO15151030A patent/NO2933252T3/no unknown
- 2010-07-12 RS RS20180292A patent/RS56981B1/sr unknown
- 2010-07-12 PL PL15151030T patent/PL2933252T3/pl unknown
- 2010-07-12 EP EP10733116.7A patent/EP2454250B1/en active Active
- 2010-07-12 MX MX2012000708A patent/MX2012000708A/es active IP Right Grant
- 2010-07-12 SI SI201032055T patent/SI3363797T1/sl unknown
- 2010-07-12 KR KR1020177018101A patent/KR20170081722A/ko not_active Ceased
- 2010-07-12 ES ES15151030T patent/ES2662397T3/es active Active
- 2010-07-12 KR KR1020127000966A patent/KR101755524B1/ko active Active
- 2010-07-12 PL PL17208659T patent/PL3363797T3/pl unknown
- 2010-07-12 ES ES17208659T patent/ES2854710T3/es active Active
- 2010-07-12 JP JP2012520706A patent/JP5745721B2/ja active Active
- 2010-07-12 PT PT107331167T patent/PT2454250E/pt unknown
- 2010-07-12 PT PT151510302T patent/PT2933252T/pt unknown
- 2010-07-12 US US12/834,673 patent/US8378108B2/en active Active
- 2010-07-12 KR KR1020187018679A patent/KR20180077338A/ko not_active Ceased
- 2010-07-12 CN CN201080040457.5A patent/CN102482257B/zh active Active
- 2010-07-12 ES ES10733116.7T patent/ES2533796T3/es active Active
- 2010-07-12 EP EP20210819.7A patent/EP3858824A1/en not_active Withdrawn
- 2010-07-12 ME MEP-2015-53A patent/ME02104B/me unknown
- 2010-07-12 SM SM20180172T patent/SMT201800172T1/it unknown
- 2010-07-12 RS RS20150247A patent/RS53951B1/sr unknown
- 2010-07-12 CA CA2767894A patent/CA2767894C/en active Active
- 2010-07-12 WO PCT/US2010/041739 patent/WO2011008709A1/en not_active Ceased
- 2010-07-12 HR HRP20150185AT patent/HRP20150185T1/hr unknown
- 2010-07-12 AR ARP100102515A patent/AR077564A1/es active IP Right Grant
- 2010-07-12 NZ NZ597533A patent/NZ597533A/en unknown
- 2010-07-12 BR BR112012000894A patent/BR112012000894A2/pt not_active IP Right Cessation
- 2010-07-12 LT LTEP15151030.2T patent/LT2933252T/lt unknown
- 2010-07-12 AU AU2010273597A patent/AU2010273597B2/en active Active
- 2010-07-12 PT PT172086597T patent/PT3363797T/pt unknown
- 2010-07-12 EP EP15151030.2A patent/EP2933252B1/en active Active
- 2010-07-12 SI SI201031622T patent/SI2933252T1/en unknown
- 2010-07-12 DK DK10733116T patent/DK2454250T3/en active
- 2010-07-12 EP EP17208659.7A patent/EP3363797B8/en active Active
- 2010-07-12 DK DK15151030.2T patent/DK2933252T3/en active
- 2010-07-12 SI SI201030851T patent/SI2454250T1/sl unknown
- 2010-07-12 PL PL10733116T patent/PL2454250T3/pl unknown
- 2010-07-12 HU HUE15151030A patent/HUE038529T2/hu unknown
- 2010-07-13 UY UY0001032786A patent/UY32786A/es not_active Application Discontinuation
-
2012
- 2012-09-13 US US13/615,259 patent/US8552196B2/en not_active Ceased
- 2012-09-14 US US13/618,841 patent/US8598360B2/en active Active
-
2013
- 2013-07-02 US US13/934,020 patent/US9067933B2/en active Active
-
2015
- 2015-03-03 JP JP2015040924A patent/JP2015098500A/ja not_active Withdrawn
- 2015-04-13 SM SM201500090T patent/SMT201500090B/xx unknown
- 2015-05-19 US US14/716,526 patent/US9586932B2/en active Active
-
2017
- 2017-01-19 JP JP2017007269A patent/JP2017071647A/ja not_active Withdrawn
- 2017-01-23 US US15/413,101 patent/US20170196844A1/en not_active Abandoned
-
2018
- 2018-03-07 CY CY20181100283T patent/CY1119889T1/el unknown
- 2018-03-09 HR HRP20180413TT patent/HRP20180413T1/hr unknown
- 2018-08-01 JP JP2018144888A patent/JP2018184464A/ja active Pending
-
2019
- 2019-08-01 US US16/529,631 patent/USRE48711E1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532931A5 (enExample) | ||
| HRP20150185T1 (hr) | Inhibitori kinaza koji reguliraju signalne puteve u apoptozi | |
| RU2018123779A (ru) | Новые соединения | |
| KR101506044B1 (ko) | Ｃ―ｆｍｓ 및/또는 ｃ―ｋｉｔ 활성 조절 화합물 및 이들의 용도 | |
| JP6195684B2 (ja) | ピラゾール化合物及びｔ型カルシウムチャンネルブロッカーとしてのそれらの使用 | |
| JP6117235B2 (ja) | Ｐｉ３ｋの活性または機能の阻害剤の使用 | |
| RU2008110915A (ru) | Новые диазаспироалканы и их применение для лечения заболеваний, опосредованных ccr8 | |
| RU2017105296A (ru) | Новые соединения | |
| JP2014062093A5 (enExample) | ||
| JP2012515786A5 (enExample) | ||
| JP2019504821A (ja) | ユビキチン特異的プロテアーゼ１阻害剤としてのプリノン | |
| JP2017530960A5 (enExample) | ||
| JP2018044008A5 (enExample) | ||
| JP2019504821A5 (enExample) | ||
| JP2017505762A5 (enExample) | ||
| CA2984259A1 (en) | Combinations of inhibitors of irak4 with inhibitors of btk | |
| RU2015129538A (ru) | Замещенные имидазопиридины в качестве ингибиторов hdm2 | |
| WO2015002754A2 (en) | Novel bicyclic bromodomain inhibitors | |
| JP2016519096A5 (enExample) | ||
| JP2006520805A5 (enExample) | ||
| JP2012528828A5 (enExample) | ||
| KR102590854B1 (ko) | Crhr2 길항제로서의 축합 환상 요소 유도체 | |
| JP2016537384A5 (enExample) | ||
| AU2023261964A1 (en) | Compounds for inhibiting kif18a | |
| RU2017120855A (ru) | Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина |